Top

Zhongxing Liao, M.D.

Department of Thoracic Radiation Oncology, Division of Radiation Oncology

About Dr. Liao

Dr. Liao's research activities aim to improve the therapeutic ratio of radiotherapy for thoracic malignancies through translational research. Specifically, her efforts focus on personalizing chemoradiotherapy for lung cancer by reducing treatment-related toxicity, and increasing cancer cure rates by using predictive biomarker strategies and advanced radiation delivery technology. She has continued her leadership role in conducting practice-changing clinical trials locally and nationally.

Dr. Liao's five most significant contributions in research include the following:

Successfully designed, led, and completed the first of the kind prospective randomized trial comparing IMRT and proton therapy for lung cancer. Dr. Liao is Principal Investigator of the first prospective randomized NCI PO1 funded multi-institutional trial “A Bayesian Randomized trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, with Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment-Related Pneumonitis and Locoregional Recurrence (NCT00915005)”. This clinical protocol compared proton and photon therapy for a “hard to treat” cancer. This protocol was critical in securing funding for her program project grant 2-P01CA021239, “Optimizing Proton Therapy,” PI Thomas Delaney; 9/25/2008−7/31/2013; $8,734,885 ($1,775,617/year). The hypothesis of this trial was based on the research findings from item 2 below, that the unique dosimetric characteristics of proton beams will reduce the dose and volume of the normal lung to radiation, hence further decreasing treatment-related lung toxicity. This protocol met the enrollment goal on 3/2014, and the first result was reported on 2016 ASCO meeting as a plenary presentation and included in the 2016 Best of ASCO. The manuscript was first submitted to the Lancet Journal with recommended transfer to the Lancet Respiratory Medicine, which she declined. The final version of the manuscript was resubmitted to JCO.
Translational research on secondary analyses on the data accumulated from protocol NCT00915005. This trial contributed greatly to the understanding of proton therapy and produced much valuable data. Dr. Liao worked with collaborators and was able to secure funding for a U19 (2U19CA021239-35, NIH/NCI, PI - Radhe Mohan, 9/25/2014-8/31/2018, $1,925,520 ($385,104/year)), and a CPRIT (RP160232, PI - Dragan Mirkovic/Pablo Yepes, 3/1/2016-2/28/2019, $835,395 ($275,114/year)) grant to perform secondary analyses on the data accumulated from this trial. Given the rapid proliferation of proton therapy facilities worldwide despite the lack of level I evidence of its effectiveness in lung cancer, Dr. Liao believes that the results are potentially practice-changing. She expects that results from ongoing analyses of secondary objectives including imaging, patient-reported outcomes, blood biomarkers, and cost effectiveness will considerably advance the state of the art in proton therapy, as will ongoing translational research to correlate biological and physical factors affecting response to protons vs. photons and radiation physics studies to assess the influence of uncertainties on proton therapy.
Established a bio-specimen repositories for biomarker research and facilitate translational research. This research effort is an expansion of the clinical trial as one of the secondary objectives and two protocols (Protocol Lab 2009-0307, PA13-0786). The aim is to identify predictive biomarkers for treatment outcome and to help select patients for the most effective treatment. The collected biospecimen including blood, plasma, serum, genome DNA, urine, and saliva are a rich resource for correlative studies to facilitate extramural funding. One example is that, using the blood samples from this study, combined with the clinical and radiation therapy dosimetric data, Dr. Liao is able to spearhead a research effort to study cardiac injury after chemoradiation for lung cancer. In the scope of the work, she has established research contract with ROCHE to use their high sensitive Cardiac Troponin kits to obtain preliminary data for extramural funding. Dr. Liao's R21 grant (1R21 CA222749-01) is entitled “Proton therapy to reduce heart damage for lung cancer patients”. Under the umbrellas of biomarker study and the infrastructure that she created, the thoracic service has accumulated a significant amount of biospecimen and clinical data on patients received concurrent chemoradiation treatment in the department of Radiation Oncology. The collaborative research effort has been expanded nationally and internationally with MGH, MAASTRO.
Becoming a national leader in clinical trials on proton therapy. Proton therapy is more costly than even the best currently available photon technology, and evidence demonstrating clinical benefit is increasingly demanded to justify the financial burden on the healthcare system. However, randomized trials comparing outcomes between different treatment technologies are practically non-existent, and trials of protons vs. photons are no exception. To establish level 1 evidence for proton therapy, we worked with the leadership of Corporate group RTOG (now NRG) and institutions and hospitals with proton facilities (total 15 now and the number continues to increase) and developed RTOG 1308, a “Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Radiochemotherapy for Inoperable Stage II-IIIB NSCLC”. This protocol was funded through CTEP. She serves as the Principle Investigator for this historical protocol in the history of particle therapy for thoracic malignancies. This trial has been active since 2014, and a total of 99 patients have been recruited to this trial. This phase III trial is probably the only opportunity for radiation oncology community to compare the survival after photons and protons chemoradiation for lung cancer patients.

Continuing her efforts in research of technological advancement including proton, Dr. Liao is leading another Randomized Phase I/II trial of image-guided, intensity-modulated photon (IMRT) or scanning beam proton therapy (IMPT) both with simultaneous integrated boost (SIB) dose escalation to the gross tumor volume (GTV) with concurrent chemotherapy for stage II/III non-small cell lung cancer (NSCLC) (MDA protocol: 2011-1058). This protocol use a novel radiation therapy technique called simultaneous integrated boost, which will delivery differential higher doses to tumor and lower dose to normal structure. This trial is significant because it is the only protocol that assess the impact of intensity modulated radiation therapy using either photon or protons, whereas the all the previous trials compared 3D Conformal proton with intensity modulated photons. She has completed the phase I portion and currently on phase II portion of this trial.
Expanded research collaborations with imaging, symptom research, and behavior science .

Dr. Liao has continued a long term collaboration with the symptom research department in the institution and was a Co-Principal Investigator on an R21 grant that investigated correlation of inflammatory cytokines and symptom burden in lung cancer patients who underwent chemoradiation. The final result has been published in the Journal of Clinical Oncology. The institution was awarded an RO1 grant entitled “Reducing the symptom burden produced by aggressive cancer therapies", 5 R01 CA026582-31, NIH/NCI, PI - Charles Cleeland, 5/1/2013-4/30/2015”. $424,012 ($84,800/year). We are the first group reporting decreased symptom burden in patients treated with proton radiation compared with those treated with IMRT or 3D CRT.

- Dr. Liao has always been interested in imaging biomarker. She has received sister institution network finding for a project “Diffusion-weighted magnetic resonance imaging for early response assessment of neoadjuvant chemoradiation for squamouse cell carcinoma of the esophagus, Sister Institution Network Fund Application, UTMDACC, 1/1/2015-12/31/2016, $99,998 ($49,999/year)”. This project is a collaborative effort with 3 institutions in China and MD Anderson Cancer Center, and this project is ongoing.

- Dr. Liao is the institutional PI for another innovative project “A Randomized Trial of Incentives for Research Participation, (1R01CA197332-01, NIH/NCI, PI - Scott D. Halpern, 7/1/2015-6/30/2020, $288,642, ($67,841/year)). This clinical trial is built upon the population of RTOG 1308m to address the question if financial incentives impacts on patient participation of clinical trial. This project is currently ongoing as well.

Dr. Liao's translational and clinical research activities have been highly productive, as evidenced in her CV by publications in highly respected peer-reviewed scientific journals, by invitations to write review articles, and by invitations to national and international meetings as keynote or panel speakers. She has accumulated rich experience and knowledge, developed leadership skills and effectiveness to conduct critical research projects and corporate trials. Dr. Liao anticipates that her research will continue its success as many completed projects mature with results presented to and accepted by the international scientific community, and ongoing projects progress smoothly.

Meet Zhongxing Liao, M.D.

In the News

Illustration of a bald patient receiving chemotherapy

What is chemoradiation? 

Illustration of proton therapy beam targeting lung cancer

4 advances in radiation therapy for lung cancer treatment

Exploring proton therapy's effectiveness on the most common form of lung cancer

Present Title & Affiliation

Primary Appointment

Department Chair ad interim, Department of Thoracic Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Committee Member, Department of Division of Radiation Oncology, 2023 Multidisciplinary Thoracic Cancers Symposium Steering Committee, Houston, TX

Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Karen H. Lu, M.D. Chair, Department of Thoracic Radiation Oncology, MD Anderson Cancer Center, Houston, Tx

Term Tenure, Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1982	Hunan Medical University, Changsha, CN, Medicine, MD

Postgraduate Training

2015-2015	Executive Education Course:Strategy for Value-Based Healthcare Delivery, Strategy for Value-Based Healthcare Delivery, Rice University, Houston, Texas
2015-2015	Clinical Safety and Effectiveness Program, University of Texas MD Anderson Cancer Center, Houston, Texas
2012-2012	Faculty Development, The Fundamentals of Finance, The University of Texas MD Anderson Cancer Center, Houston, Texas
2012-2012	Faculty Development, Beyond the CV: Behavioral Interviewing of Faculty Candidates, The University of Texas MD Anderson Cancer Center, Houston, Texas
2012-2012	Management, Physician in Management Seminar, American College of Physician Executives, Chicago, Illinois
2007-2008	Faculty Leadership Academy, Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, Texas
1995-1999	Clinical Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1994-1995	Clinical Internship, Internal Medicine, The University of Kansas School of Medicine-Wichita, Wichita, Kansas
1993-1994	Clinical Fellowship, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1989-1993	Research Fellowship, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1983-1986	Radiation Oncology Residency, Hunan Tumor Hospital & Institution, Changsha

Board Certifications

1999	American Board of Radiology - Radiation Oncology

Experience & Service

Academic Appointments

The Elza A. and Ina Shackelford Freeman Endowed Professorship in Lung Cancer, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024

Associate Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2009

Assistant Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2004

Attending Radiation Oncologist, Department of Radiation Oncology, Hunan Tumor Hospital & Institution, Changsha, 1986 - 1989

Administrative Appointments/Responsibilities

Department Chair ad interim, Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

Thoracic Section Chief ad interim, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2023

Deputy Department Chair of Clinical Research, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Director for Clinical Research, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Committee Chair, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Director of Clinical Research ad interim, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

Committee Chair, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Deputy Department Chair of Clinical Affairs, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Medical Director, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2016

Staff/Radiation Oncology, Department of Radiation Oncology, The Oakbend Radiation Oncology Treatment Center, Houston, TX, 2003 - 2009

Clinical Section Chief Thoracic, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2006

Other Appointments/Responsibilities

Committee Member, 2023 Multidisciplinary Thoracic Cancers Symposium Steering Committee, Houston, TX, 2022 - Present

Thoracic Section Chief ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2023

Committee Member, International Association for the Study of Lung Cancer, Houston, TX, 2021 - Present

Chair, International Educational Subcommittee ASTRO, Houston, 2016 - 2018

Chair, Multidisciplinary Thoracic Cancers Symposium Steering Committee, San Francisco, CA, 2015 - 2017

Member, ASTRO/Best of ASTRO Licensing Taskforce, Fairfax, VA, 2014 - Present

Staff/Radiation Oncology, The Woodlands Radiation Oncology Treatment Center, Houston, TX, 2000 - Present

Institutional Committee Activities

Co-Chair, Search Committee for GURO Chair, 2024 - 2024

Member, Community of Chairs Committee, 2023 - Present

Member, Endowed Positions & Awards Committee (EPAC), 2021 - 2025

Executive Committee Member, Advisory Council for Clinical Research Leaders (ACCRL), 2021 - Present

Member, Advisory Clinical Research Council (ACRC), 2020 - 2020

Member, Data Safety Monitor Committee, 2020 - 2023

Co-Chair, Radiation Oncology Faculty Search Committee, 2019 - Present

Member, NCTN Steering and Operations Committee, 2018 - Present

Member, NCTN LAPS Executive Committee, 2018 - Present

Member, Credentials Committee of the Medical Staff Member, 2017 - Present

Member, ECOT Capital Budget SubCommittee, 2016 - Present

Member, Mandatory Federal Reporting Committee, 2016 - Present

Member, ECMS Committee, 2016 - Present

Member, PRS Retirement Committee, 2015 - 2018

Member, Radiation Oncology Quality Care Committee, 2015 - 2017

Member, Medical Quality Planning Committee, 2014 - Present

Member, International Advisory Board, 2014 - 2014

Member, Head, Division of Internal Medicine Search Committee, 2013 - 2014

Member, Radiation Oncology Department Executive Leadership Committee, 2013 - 2017

Faculty Senator, Faculty Senate, 2011 - 2014

Member, Vice President for Clinical Research Search Committee, 2010 - 2011

Member, Clinical Faculty Review Committee, 2010 - 2011

Member, PRS Budget & Finance Committee, 2009 - 2015

Member, Data Safety Monitoring Board, 2008 - 2010

Member, The Executive Committee for Medical Staff, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, MDACC/HCHD Quarterly Administrative/Medical Advisory Committee, 2007 - 2009

Member, Revenue Cycle Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Chair, Clinical Operations Committee, Department of Radiation Oncology, 2007 - 2016

Member, Uncompensated Care Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2009

Member, Harris County Health District (HCHD/MDACC) Joint Operation Committee, 2007 - 2010

Member (back up for Dr. Adam Garden), Credential Committee for Medical Staff, 2006 - 2008

Member, IRB Data Safety Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2008

Member, Steering Committee for China, Extramural Program, The University of Texas MD Anderson Cancer Center, 2004 - 2004

Member, Asia Task Force, Extramural Program, The University of Texas MD Anderson Cancer Center, 1999 - 1999

Honors & Awards

2021	The 2021 Samuel J. Hassenbusch, III, Leadership & Institutional Service award, The physician Referral Service, The UT MDACC
2020	Top Doctor, Top Doctor Awards
2019	Gold Medal Award, Gilbert H. Fletcher Society
2018	Fellow, American Society for Radiation Oncology
2018	President's Recognition of Faculty Excellence, The University of Texas MD Anderson Cancer Center
2018	Fellow of American Association of Woman Radiologists, American Association of Woman Radiologists, ACR
2014	Provost's Distinguished Faculty Mentoring Awards Nominee, University of Texas MD Anderson Cancer Center
2011	The Marie Sklodowska-Curie Award-American Association for Women Radiologists, American Association for Women Radiologists
2007	AAWR Research and Education Foundation Professional Leadership Award, AAMC Professional Development Seminar for Mid-Career Women Faculty, American Association of Women Radiologist
2007	Outstanding Contribution to Radiation Oncology Education for China Award, Chinese Society of Therapeutic Radiology and Oncology
2007	Outstanding International Collaboration Award, Chinese Society of Therapeutic Radiology and Oncology
2004	Travel Grant - International Society of Gastrointestinal Oncology, International Society of Gastrointestinal Oncology
2003	Best Doctors in America
2003	AAWR Research and Education Foundation Professional Leadership Award, AAMC Professional Development Seminar for Early Career Faculty, American Association for Women Radiologist
1989	World Health Organization Fellowship, World Health Organization
1980	Honor Student, Hunan Medical University

Selected Publications

Peer-Reviewed Articles

Abana, CO, Carriere, P, Damen, PJ, van Rossum, P, Yoder, A, Bravo, PL, Wei, X, Pollard-Larkin, JM, Nitsch, PL, Murphy, MB, Hofstetter, WL, Liao, Z, Lin, SH. Comparative Outcomes and Toxicity in Patients With Esophageal Cancer After Trimodality Therapy With Step-and-Shoot Intensity-Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy. Clinical Oncology 38, 2025. e-Pub 2025.
Salazar, RM, Nair, SS, Leone, A, Xu, T, Mumme, R, Duryea, J, De, BS, Corrigan, KL, Rooney, MK, Ning, M, Das, P, Holliday, EB, Liao, Z, Court, LE, Niedzielski, JS. Performance Comparison of 10 State-of-the-Art Machine Learning Algorithms for Outcome Prediction Modeling of Radiation-Induced Toxicity. Advances in Radiation Oncology 10(2), 2025. e-Pub 2025. PMID: 39717195.
Kim, C, Li, Y, Xu, T, Liao, Z. Bayesian Nonparametric Model for Heterogeneous Treatment Effects With Zero-Inflated Data. Statistics in Medicine 43(30):5968-5982, 2024. e-Pub 2024. PMID: 39608809.
Chen, X, Zhao, Y, Baroudi, H, El Basha, MD, Daniel, A, Gay, SS, Yu, C, Wang, H, Phan, J, Choi, S, Goodman, C, Zhang, X, Niedzielski, JS, Shete, S, Court, LE, Liao, Z, Löfman, F, Balter, PA, Yang, J. Comparison of Vendor-Pretrained and Custom-Trained Deep Learning Segmentation Models for Head-and-Neck, Breast, and Prostate Cancers. Diagnostics 14(24), 2024. e-Pub 2024.
Ning, M, Odwuor, A, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Welsh, J, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Lee, PP. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers 16(21), 2024. e-Pub 2024.
Soto-Lanza, F, Glick, L, Chan, C, Zhong, L, Wilson, NR, Faiz, S, Gandhi, S, Naing, A, Heymach, JV, Shannon, VR, Franco Vega, M, Liao, Z, Lin, SH, Palaskas, NL, Wu, J, Shroff, G, Altan, M, Sheshadri, A. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical Lung Cancer 25(7):624-633.e2, 2024. e-Pub 2024. PMID: 39183094.
Nead KT, Kim T, Joo L, McDowell T, Wong J, Chan IC, Brock E, Zhao J, Xu T, Tang C, Lee CL, Abe JI, Bolton KL, Liao Z, Scheet P, Lin SH. Impact of Cancer Therapy on Clonal Hematopoiesis Mutations and Subsequent Clinical Outcomes. Blood Adv 8(19):5215-5224, 2024. e-Pub 2024. PMID: 38830141.
Frank, SJ, Das, IJ, Simone, C, Davis, BJ, Deville, C, Liao, Z, Lo, SS, McGovern, SL, Parikh, RR, Reilly, M, Small, W, Schechter, NR. ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy. International Journal of Particle Therapy 13, 2024. e-Pub 2024. PMID: 39347377.
Iskander GM, Cavazos A, Ejezie CL, Cox V, Cheng H, Perez S, Koong AC, Nguyen J, Herman J, Beddar S, Liao Z, Yeboa DN. Protocol-in-a-Day Workshop: Expediting IRB Approval for Junior and Senior Faculty. J Cancer Educ. e-Pub 2024. PMID: 38914893.
Weng J, Mesko S, Chronowski G, Lee P, Choi S, Das P, Koong AC, French K, Aloia T, Ehlers R, Elrod-Joplin D, Kerr A, Smith R, Martinez W, Bloom E, Shah SJ, Ning MS, Liao Z, Herman J, Moningi S, Moreno AC, Nguyen QN. Optimizing Outpatient Radiation Oncology Consult Workflow by Using Time-Driven Activity-Based Costing: Efficiency and Financial Impacts. JCO Oncol Pract 20(5):OP2300037, 2024. e-Pub 2024. PMID: 38330252.
Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
Abana CO, Damen PJ, van Rossum PS, Bravo PL, Wei X, Pollard-Larkin JM, Nitsch PL, Murphy MB, Hofstetter WL, Liao Z, Lin SH. Esophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy. Int J Part Ther 11:100009, 2024. e-Pub 2024. PMID: 38757075.
Maragno D, Buti G, Birbil SI, Liao Z, Bortfeld T, den Hertog D, Ajdari A. Embedding machine learning based toxicity models within radiotherapy treatment plan optimization. Phys Med Biol 69(7), 2024. e-Pub 2024. PMID: 38412530.
Damen PJJ, van Rossum PSN, Chen Y, Abana CO, Liao Z, Hobbs BP, Mohan R, Blum-Murphy M, Hofstetter WL, Lin SH. Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer. Int J Part Ther 11:100012, 2024. e-Pub 2024. PMID: 38757082.
Wang X, van Rossum PSN, Chu Y, Hobbs BP, Grassberger C, Hong TS, Liao Z, Yang J, Zhang X, Netherton T, Mohan R, Lin SH. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 118(2):368-377, 2024. e-Pub 2024. PMID: 37652304.
Chen X, Mumme RP, Corrigan KL, Mukai-Sasaki Y, Koutroumpakis E, Palaskas NL, Nguyen CM, Zhao Y, Huang K, Yu C, Xu T, Daniel A, Balter PA, Zhang X, Niedzielski JS, Shete SS, Deswal A, Court LE, Liao Z, Yang J. Deep learning-based automatic segmentation of cardiac substructures for lung cancers. Radiother Oncol 191:110061, 2024. e-Pub 2024. PMID: 38122850.
Zhu J, Wang Y, Sun H, Zhang Y, Zhang W, Shen W, Yang N, Tan B, Su X, Li L, Dong W, Ma J, Zhang J, Zhao L, Sun D, Yang P, Peng L, Li B, Huang W, Wang Q, Liao Z. Surgery versus radiotherapy for limited-stage small cell esophageal carcinoma: a multicenter, retrospective, cohort study in China (ChiSCEC). Int J Surg 110(2):956-964, 2024. e-Pub 2024. PMID: 37995095.
Chen, X, Weng, JK, Sobremonte, A, Lee, B, Hughes, N, Mohammedsaid, M, Zhao, Y, Wang, X, Zhang, X, Niedzielski, JS, Shete, S, Court, LE, Liao, Z, Lee, PP, Yang, J. Case report. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 39351356.
Tate, MK, Hernandez, M, Chang, JY, Lin, SH, Liao, Z, Koshy, SM, Skinner, H, Chun, SG. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer. Anticancer research 44(1):133-137, 2024. e-Pub 2024. PMID: 38159979.
He Y, Cazoulat G, Wu C, Svensson S, Almodovar-Abreu L, Rigaud B, McCollum E, Peterson C, Wooten Z, Rhee DJ, Balter P, Pollard-Larkin J, Cardenas C, Court L, Liao Z, Mohan R, Brock K. Quantifying the Effect of 4-Dimensional Computed Tomography-Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 118(1):231-241, 2024. e-Pub 2024. PMID: 37552151.
Ladbury C, Li R, Danesharasteh A, Ertem Z, Tam A, Liu J, Hao C, Li R, McGee H, Sampath S, Williams T, Glaser S, Khasawneh M, Liao Z, Lee P, Ryckman J, Shaikh P, Amini A. Explainable Artificial Intelligence to Identify Dosimetric Predictors of Toxicity in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of RTOG 0617. Int J Radiat Oncol Biol Phys 117(5):1287-1296, 2023. e-Pub 2023. PMID: 37406826.
Weiß A, Löck S, Xu T, Liao Z, Hoffmann AL, Troost EGC. Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy. Radiother Oncol 190:110013. e-Pub 2023. PMID: 37972734.
Altan M, Soto F, Xu T, Wilson N, Franco-Vega MC, Simbaqueba Clavijo CA, Shannon VR, Faiz SA, Gandhi S, Lin SH, Lopez P, Zhong L, Akhmedzhanov F, Godoy MCB, Shroff GS, Wu J, Khawaja F, Kim ST, Naing A, Heymach JV, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clin Oncol (R Coll Radiol) 35(10):630-639, 2023. e-Pub 2023. PMID: 37507279.
Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
Peng L, Bin Y, Ding P, Chen L, Zeng H, Xu Z, Ji L, Gao X, Liu P, Wang Y, Zhang S, Liao Z, Xia X, Zhang R, Tong F, Dong X. Integrated circulating tumor DNA and T cell repertoire predict radiotherapeutic response and outcome in non-small cell lung cancer patients with brain metastasis. Cancer Commun (Lond) 43(5):625-629, 2023. e-Pub 2023. PMID: 36815673.
Rimner A, Moore ZR, Lobaugh S, Geyer A, Gelblum DY, Abdulnour RE, Shepherd AF, Shaverdian N, Wu AJ, Cuaron J, Chaft JE, Zauderer MG, Eng J, Riely GJ, Rudin CM, Els NV, Chawla M, McCune M, Li H, Jones DR, Sopka DM, Simone CB, Mak R, Weinhouse GL, Liao Z, Gomez DR, Zhang Z, Paik PK. Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis. Int J Radiat Oncol Biol Phys. e-Pub 2023. PMID: 36889516.
Geng H, Liao Z, Nguyen QN, Berman AT, Robinson C, Wu A, Nichols RC, Willers H, Mohammed N, Mohindra P, Xiao Y. Implementation of Machine Learning Models to Ensure Radiotherapy Quality for Multicenter Clinical Trials: Report from a Phase III Lung Cancer Study. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831358.
Zhu, XR, Li, Y, Yang, M, Whitaker, TJ, Taylor, PA, Zhang, X, Poenisch, F, Sahoo, N, Liao, Z, Chang, JY. Stereotactic body proton therapy for early-stage non-small cell lung cancer - Technical challenges and solutions. Journal of Radiosurgery and SBRT 9(1):75-82, 2023. e-Pub 2023.
He Y, Anderson BM, Cazoulat G, Rigaud B, Almodovar-Abreu L, Pollard-Larkin J, Balter P, Liao Z, Mohan R, Odisio B, Svensson S, Brock KK. Optimization of mesh generation for geometric accuracy, robustness, and efficiency of biomechanical-model-based deformable image registration. Med Phys 50(1):323-329, 2023. e-Pub 2023. PMID: 35978544.
De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
Puckett LL, Titi M, Kujundzic K, Dawes SL, Gore EM, Katsoulakis E, Park JH, Solanki AA, Kapoor R, Kelly M, Palta J, Chetty IJ, Jabbour SK, Liao Z, Movsas B, Thomas CR, Timmerman RD, Werner-Wasik M, Kudner R, Wilson E, Simone CB. Consensus Quality Measures and Dose Constraints for Lung Cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology (ASTRO) Expert Panel. Pract Radiat Oncol 13(5):413-428, 2023. e-Pub 2023. PMID: 37075838.
Xiao N, Pei Z, Lu W, Fang R, Jin Y, Zhou G, Meng X, Ng SP, Xing L, Liao Z, Sijtsema NM, Yang P. Editorial: Application of radiomics in understanding tumor biological behaviors and treatment response. Front Oncol 13:1257447, 2023. e-Pub 2023. PMID: 37664068.
Moran JA, Adams DL, Edelman MJ, Lopez P, He J, Qiao Y, Xu T, Liao Z, Gardner KP, Tang CM, Lin SH. Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. JCO Precis Oncol 6:e2200457, 2022. e-Pub 2022. PMID: 36516370.
Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol 176:149-156, 2022. e-Pub 2022. PMID: 36209942.
Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
Ajdari A, Liao Z, Mohan R, Wei X, Bortfeld T. Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization. Phys Med Biol 67(18), 2022. e-Pub 2022. PMID: 35947984.
Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep 3(9):100391, 2022. e-Pub 2022. PMID: 36089921.
Lin, SH, Liao, K, Lei, X, Verma, V, Shaaban, SG, Lee, PP, Chen, A, Koong, A, Hoftstetter, WL, Frank, SJ, Liao, Z, Shih, YT, Giordano, SH, Smith, GL. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. International Journal of Particle Therapy 9(1):18-27, 2022. e-Pub 2022. PMID: 35774487.
Chen M, Wang Z, Jiang S, Sun J, Wang L, Sahoo N, Brandon Gunn G, Frank SJ, Xu C, Chen J, Nguyen QN, Chang JY, Liao Z, Ronald Zhu X, Zhang X. Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Sci Rep 12(1):9178, 2022. e-Pub 2022. PMID: 35655073.
Monti S, Xu T, Mohan R, Liao Z, Palma G, Cella L. Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406605.
Monti S, Xu T, Liao Z, Mohan R, Cella L, Palma G. On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients. Radiother Oncol 167:219-225, 2022. e-Pub 2022. PMID: 34979216.
Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z, Yang X, Liu L, He H, Liao Z, Guan N, Kong Y, Wang W, Chen J, He H, Qiu G, Zeng M, Pu J, Hu W, Bao Y, Liu Z, Ma J, Jiang H, Du X, Hu J, Zhuang T, Cai J, Huang J, Tao H, Liu Y, Liang X, Zhou J, Tao G, Zheng X, Chen M. A phase III multicenter randomized clinical trial of 60 Gy vs 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Clin Cancer Res. e-Pub 2022. PMID: 35190815.
Imanishi M, Cheng H, Kotla S, Deswal A, Le NT, Chini E, Ko KA, Samanthapudi VSK, Lee LL, Herrmann J, Xu X, Reyes-Gibby C, Yeung SJ, Schadler KL, Yusuf SW, Liao Z, Nurieva R, Amir ED, Burks JK, Palaskas NL, Cooke JP, Lin SH, Kobayashi M, Yoshimoto M, Abe JI. Radiation therapy induces immunosenescence mediated by p90RSK. Front Cardiovasc Med 9:988713, 2022. e-Pub 2022. PMID: 36426217.
Lin SH, Liao K, Lei X, Verma V, Shaaban S, Lee P, Chen AB, Koong AC, Hoftstetter WL, Frank SJ, Liao Z, Shih YT, Giordano SH, Smith GL. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. Int J Part Ther 9(1):18-27, 2022. e-Pub 2022. PMID: 35774487.
Koutroumpakis E, Xu T, Lopez-Mattei J, Pan T, Lu Y, Irizarry-Caro JA, Mohan R, Zhang X, Meng QH, Lin R, Xu T, Deswal A, Liao Z. Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. Front Cardiovasc Med 9:1071701, 2022. e-Pub 2022. PMID: 36531700.
Wu, Lr, Zhu, J, Rudqvist, N, Welsh, J, Lee, PP, Liao, Z, Xu, T, Jiang, M, Zhu, X, Pan, X, Li, P, Zhou, Z, He, X, Yin, R, Feng, J. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Frontiers in immunology 12, 2021. e-Pub 2021. PMID: 34733273.
Geng, H, Giaddui, T, Cheng, C, Zhong, H, Ryu, S, Liao, Z, Yin, FF, Gillin, M, Mohan, R, Xiao, Y. A comparison of two methodologies for radiotherapy treatment plan optimization and QA for clinical trials. Journal of applied clinical medical physics 22(10):329-337, 2021. e-Pub 2021. PMID: 34432946.
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, Trials Group SLC. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
He Y, Cazoulat G, Wu C, Peterson C, McCulloch M, Anderson B, Pollard-Larkin J, Balter P, Liao Z, Mohan R, Brock K. Geometric and dosimetric accuracy of deformable image registration between average-intensity images for 4DCT-based adaptive radiotherapy for non-small cell lung cancer. J Appl Clin Med Phys 22(8):156-167, 2021. e-Pub 2021. PMID: 34310827.
Palma, G, Monti, S, Pacelli, R, Liao, Z, Deasy, JO, Mohan, R, Cella, L. Radiation pneumonitis in thoracic cancer patients. Cancers 13(14), 2021. e-Pub 2021. PMID: 34298767.
Cella, L, Monti, S, Xu, T, Liuzzi, R, Stanzione, A, Durante, M, Mohan, R, Liao, Z, Palma, G. Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. Radiotherapy and Oncology 160:148-158, 2021. e-Pub 2021. PMID: 33979653.
Garant, A, Spears, GM, Routman, DM, Whitaker, TJ, Liao, Z, Harmsen, WS, Liu, A, Haddock, MG, Hallemeier, C, Lin, SH, Merrell, KW. A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. Practical radiation oncology 11(4):e415-e425, 2021. e-Pub 2021. PMID: 33486102.
Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, Lopez-Mattei JC, Mohan R, Liao Z. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys. e-Pub 2021. PMID: 34302893.
Yang Z, Zhang Y, Li R, Yisikandaer A, Ren B, Sun J, Li J, Chen L, Zhao R, Zhang J, Xia X, Liao Z, Carbone DP. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial. Neuro Oncol 23(6):967-978, 2021. e-Pub 2021. PMID: 33331923.
Augustyn, A, Adams, DL, He, J, Qiao, Y, Verma, V, Liao, Z, Tang, CM, Heymach, JV, Tsao, A, Lin, SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non–Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clinical Lung Cancer 22(3):e451-e465, 2021. e-Pub 2021. PMID: 32798130.
Cho, D, Kim, S, Durrani, S, Liao, Z, Milbury, K. Associations Between Spirituality, Mindfulness, and Psychological Symptoms Among Advanced Lung Cancer Patients and Their Spousal Caregivers. Journal of pain and symptom management 61(5):898-908.e1, 2021. e-Pub 2021. PMID: 33039605.
Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 22(3):225-233, 2021. e-Pub 2021. PMID: 32727706.
Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
Pan, T, Lu, Y, Thomas, MA, Liao, Z, Luo, D. New Data-Driven Gated PET/CT Free of Misregistration Artifacts. International Journal of Radiation Oncology Biology Physics 109(5):1638-1646, 2021. e-Pub 2021. PMID: 33186619.
Ning MS, Das P, Rosenthal DI, Dabaja BS, Liao Z, Chang JY, Gomez DR, Klopp AH, Gunn GB, Allen PK, Nitsch PL, Natter RB, Briere TM, Herman JM, Wells R, Koong AC, McAleer MF. Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. J Natl Compr Canc Netw:1-9. e-Pub 2021. PMID: 33878727.
Chetvertkov, MA, Vassiliev, ON, Yang, J, Wang, H, Liu, A, Liao, Z, Mohan, R. Impact of intra-fractional motion on dose distributions in lung IMRT. Journal of Radiotherapy in Practice 20(1):12-16, 2021. e-Pub 2021. PMID: 34168519.
Yeboa DN, Akinfenwa CA, Nguyen J, Amaya D, de Gracia B, Ning M, Cox V, De B, Smith BD, Lin L, Beddar S, Hoang H, Koong A, Liao Z. Effectively Conducting Oncology Clinical Trials during the COVID-19 Pandemic. Adv Radiat Oncol:100676. e-Pub 2021. PMID: 33686374.
Wong SL, Alshaikhi J, Grimes H, Amos RA, Poynter A, Rompokos V, Gulliford S, Royle G, Liao Z, Sharma RA, Mendes R. Retrospective Planning Study of Patients with Superior Sulcus Tumours Comparing Pencil Beam Scanning Protons to Volumetric-Modulated Arc Therapy. Clin Oncol (R Coll Radiol) 33(3):e118-e131, 2021. e-Pub 2021. PMID: 32798157.
Gjyshi, O, Xu, T, Elhammali, A, Boyce-Fappiano, DR, Chun, SG, Gandhi, S, Lee, PP, Chen, A, Lin, SH, Chang, JY, Tsao, A, Gay, CM, Zhu, XR, Zhang, X, Heymach, JV, Fossella, FV, Lu, C, Nguyen, Q, Liao, Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology 16(2):269-277, 2021. e-Pub 2021. PMID: 33198942.
Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. e-Pub 2021. PMID: 33707003.
De B, Kaiser KW, Ludmir EB, Yeboa DN, Tang C, Hoffman KE, Liao Z, Koong AC, Smith BD. Radiotherapy clinical trial enrollment during the COVID-19 pandemic. Acta Oncol:1-4. e-Pub 2020. PMID: 33356801.
Pan T, Lu Y, Thomas A, Liao Z, Luo D. A new data-driven gated PET/CT free of misregistration artifacts. International Journal of Radiation Oncology Biology Physics, 2020. e-Pub 2020.
Gironda DJ, Adams DL, He J, Xu T, Gao H, Qiao Y, Komaki R, Reuben JM, Liao Z, Blum-Murphy M, Hofstetter WL, Tang CM, Lin SH. Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. J Transl Med 18(1):413, 2020. e-Pub 2020. PMID: 33148307.
Wang X, Palaskas NL, Yusuf SW, Abe JI, Lopez-Mattei J, Banchs J, Gladish GW, Lee P, Liao Z, Deswal A, Lin SH. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J Thorac Oncol 15(10):1682-1690, 2020. e-Pub 2020. PMID: 32599073.
Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer. Elsevier. e-Pub 2020.
Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol 154:187-193. e-Pub 2020. PMID: 32916236.
Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 5(5):951-958, 2020. e-Pub 2020. PMID: 33083658.
Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck 42(8):1939-1953, 2020. e-Pub 2020. PMID: 32129548.
Liao Z, Rivin Del Campo E, Salem A, Pang Q, Liu H, Lopez Guerra JL. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer 146:230-235, 2020. e-Pub 2020. PMID: 32585497.
Noticewala SS, Koong AC, Bloom ES, Choi S, Chronowski G, Ghafar RA, Guadagnolo BA, Gunn GB, Klopp A, Lee P, Li J, Liao Z, Ludmir EB, McAleer MF, Nguyen QN, Ning MS, Robinson IJ, Rosenthal DI, Shah SJ, Woodward WA, Zaebst DJ, Dabaja BS, Das P. Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Adv Radiat Oncol 5(4):567-572, 2020. e-Pub 2020. PMID: 32775771.
Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi B. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer 21(4):e294-e301, 2020. e-Pub 2020. PMID: 32089476.
Milbury K, Li Y, Durrani S, Liao Z, Tsao AS, Carmack C, Cohen L, Bruera E. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist. e-Pub 2020. PMID: 32621630.
Ning MS, McAleer MF, Jeter MD, Minsky BD, Ghafar RA, Robinson IJ, Nitsch PL, Zaebst DJ, Todd SE, Nguyen J, Lin SH, Liao Z, Lee P, Gunn GB, Klopp AH, Dabaja BS, Nguyen QN, Chronowski GM, Bloom ES, Koong AC, Das P. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 148:252-257, 2020. e-Pub 2020. PMID: 32474129.
Niedzielski JS, Wei X, Xu T, Gomez DR, Liao Z, Bankson JA, Lai SY, Court LE, Yang J. Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC. Acta Oncol:1-8. e-Pub 2020. PMID: 32678696.
Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T. Multifactorial deep learning reveals pan-cancer genomic tumor clusters with distinct immunogenomic landscape and response to immunotherapy. Clin Cancer Res 26(12):2908-2920, 2020. e-Pub 2020. PMID: 31911545.
Wang Z, Chen M, Sun J, Jiang S, Wang L, Wang X, Sahoo N, Gunn GB, Frank SJ, Nguyen QN, Liao Z, Chang JY, Zhu XR, Zhang X. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol 146:200-204, 2020. e-Pub 2020. PMID: 32220701.
Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020. PMID: 32160096.
Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol 43(4):231-235, 2020. e-Pub 2020. PMID: 31990759.
Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY. Extracellular Vesicle Tetraspanin-8 Level Predicts Distant Metastasis in Non-Small Cell Lung Cancer after Concurrent Chemoradiation. Sci Adv 6(11):eaaz6162, 2020. e-Pub 2020. PMID: 32195353.
Gjyshi O, Liao Z. Proton therapy for locally advanced non-small cell lung cancer. Br J Radiol 93(1107):20190378, 2020. e-Pub 2020. PMID: 31430188.
Chen M, Yang J, Liao Z, Chen J, Xu C, He X, Zhang X, Zhu RX, Li H. Anatomic change over the course of treatment for non-small cell lung cancer patients and its impact on intensity-modulated radiation therapy and passive-scattering proton therapy deliveries. Radiat Oncol 15(1):55, 2020. e-Pub 2020. PMID: 32138753.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
Pasalic D, Lu Y, Betancourt-Cuellar SL, Taku N, Mesko SM, Bagley AF, Chance WW, Allen PK, Tang C, Antonoff MB, Balter PA, Mehran RJ, Welsh JW, Liao Z, Gomez DR, Erasmus JJ, Nguyen QN. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol 145:178-185. e-Pub 2020. PMID: 32044530.
Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res 30(2):146-162, 2020. e-Pub 2020. PMID: 31949285.
Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez DR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo Jr BW, Lin SH, Alizadeh AA, Diehn M. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer 1:176-183, 2020. e-Pub 2020.
Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-small Cell Lung Cancer: A Phase II Randomized Trial. Int J Radiat Oncol Biol Phys 106(1):100-107, 2020. e-Pub 2020. PMID: 31627177.
Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial. Int J Radiat Oncol Biol Phys. e-Pub 2019. PMID: 31678224.
Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol. e-Pub 2019. PMID: 31479748.
Ludmir EB, Adlakha EK, Chun SG, Reed VK, Arzu IY, Ahmad N, Bloom E, Chronowski GM, Delclos ME, Mayo LL, Schlembach PJ, Liao Z, Koong AC, Herman JM, Shah SJ. Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses. Acta Oncol 58(8):1135-1137, 2019. e-Pub 2019. PMID: 30958082.
Palma G, Monti S, Xu T, Scifoni E, Yang P, Hahn SM, Durante M, Mohan R, Liao Z, Cella L. Spatial Dose Patterns Associated With Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Photon Therapy With Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 104(5):1124-1132, 2019. e-Pub 2019. PMID: 30822531.
Yeboa DN, Liao Z, Court L, Holliday EB, Spelman A, Herman J. Protocol-in-a-Day Workshop: A Lean Approach to Clinical Trial Development and Focus on Junior Faculty Development. Adv Radiat Oncol 4(3):439-442, 2019. e-Pub 2019. PMID: 31360796.
Elhammali A, Blanchard P, Yoder A, Liao Z, Zhang X, Ronald Zhu X, Allen PK, Jeter M, Welsh J, Nguyen QN. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol 136:136-142, 2019. e-Pub 2019. PMID: 31015115.
Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, Wang J, Yuan Z, Wang P, Lin SH. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 17:17-23, 2019. e-Pub 2019. PMID: 31080898.
Ning MS, Gomez DR, Shah AK, Kim CR, Palmer MB, Thaker NG, Grosshans DR, Liao Z, Chapman BV, Brooks ED, Tang C, Rosenthal DI, Garden AS, Frank SJ, Gunn GB. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. Int J Radiat Oncol Biol Phys 104(4):724-733, 2019. e-Pub 2019. PMID: 30557675.
Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol 5(6):872-878, 2019. e-Pub 2019. PMID: 31021390.
Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H, Xia X, Yang L, Zhang J, Husain H, Liao Z, Futreal A, Huang J, Yi X, Xu B. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. e-Pub 2019. PMID: 31241775.
Deng W, Xu C, Liu A, van Rossum PSN, Deng W, Liao Z, Koong AC, Mohan R, Lin SH. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiother Oncol 133:9-15, 2019. e-Pub 2019. PMID: 30935587.
Milbury K, Liao Z, Shannon V, Mallaiah S, Nagarathna R, Li Y, Yang C, Carmack C, Bruera E, Cohen L. Dyadic yoga program for patients undergoing thoracic radiotherapy and their family caregivers: Results of a pilot randomized controlled trial. Psychooncology 28(3):615-621, 2019. e-Pub 2019. PMID: 30659739.
Tucker SL, Xu T, Paganetti H, Deist T, Verma V, Choi N, Mohan R, Liao Z. Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. Int J Radiat Oncol Biol Phys 103(2):403-410, 2019. e-Pub 2019. PMID: 30291994.
Krafft SP, Rao A, Stingo F, Briere TM, Court LE, Liao Z, Martel MK. Erratum: "The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis" [Med. Phys. Vol. 45(11):5317-5324 (2018)]. Med Phys 46(2):1079, 2019. e-Pub 2019. PMID: 30730574.
Ge S, Wang X, Liao Z, Zhang L, Sahoo N, Yang J, Guan F, Mohan R. Potential for Improvements in Robustness and Optimality of Intensity-Modulated Proton Therapy for Lung Cancer with 4-Dimensional Robust Optimization. Cancers (Basel) 11(1), 2019. e-Pub 2019. PMID: 30609652.
Yang P, Xu T, Gomez DR, Deng W, Wei X, Elhalawani H, Jin H, Guan F, Mirkovic D, Xu Y, Mohan R, Liao Z. Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 103(1):123-131, 2019. e-Pub 2019. PMID: 30165127.
Yepes P, Adair A, Frank SJ, Grosshans DR, Liao Z, Liu A, Mirkovic D, Poenisch F, Titt U, Wang Q, Mohan R. Fixed- versus Variable-RBE Computations for Intensity Modulated Proton Therapy. Adv Radiat Oncol 4(1):156-167, 2019. e-Pub 2019. PMID: 30706024.
Luo Y, Xu Y, Liao Z, Gomez D, Wang J, Jiang W, Zhou R, Williamson R, Court LE, Yang J. Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis?. Acta Oncol 58(1):81-87, 2019. e-Pub 2019. PMID: 30306817.
Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 10(1):552, 2019. e-Pub 2019. PMID: 30696827.
Deng W, Xu T, Xu Y, Wang Y, Liu X, Zhao Y, Yang P, Liao Z. Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach. J Thorac Oncol 13(12):1968-1974, 2018. e-Pub 2018. PMID: 30194035.
Krafft SP, Rao A, Stingo F, Briere TM, Court LE, Liao Z, Martel MK. The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis. Med Phys 45(11):5317-5324, 2018. e-Pub 2018. PMID: 30133809.
Kong FS, Moiseenko V, Zhao J, Milano MT, Li L, Rimner A, Das S, Li XA, Miften M, Liao Z, Martel M, Bentzen SM, Jackson A, Grimm J, Marks LB, Yorke E. Organs at risk considerations for thoracic stereotactic body radiation therapy: what is safe for lung parenchyma?. Int J Radiat Oncol Biol Phys S0360-3016(18):34014-8. e-Pub 2018. PMID: 30496880.
Liao Z. Considerations in randomized trials to test technologies. J Thorac Dis 10(Suppl 26):S3308, 2018. e-Pub 2018. PMID: 30370145.
Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9(1):3114, 2018. e-Pub 2018. PMID: 30082701.
Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open 1(4):e181390, 2018. e-Pub 2018. PMID: 30646121.
Deng W, Xu T, Wang Y, Xu Y, Yang P, Gomez D, Liao Z. Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer. Lung Cancer 122:60-66, 2018. e-Pub 2018. PMID: 30032846.
Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 101(3):558-563, 2018. e-Pub 2018. PMID: 29680255.
Boonyawan K, Gomez DR, Komaki R, Xu Y, Nantavithya C, Allen PK, Mohan R, Liao Z. Clinical and Dosimetric Factors Predicting Grade =2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys 101(4):919-926, 2018. e-Pub 2018. PMID: 29976504.
Sio TT, Prayongrat A, Zhang Y, Lin Q, Xu T, Liao Z, Yue J. The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer?. Clin Lung Cancer 19(4):289-293, 2018. e-Pub 2018. PMID: 29665993.
Liao Z, Mohan R. Future of Protons Depends on Precision. J Clin Oncol 36(19):2002, 2018. e-Pub 2018. PMID: 29746224.
Liao Z, Mohan R. Reply to R. Rengan et al. J Clin Oncol 36(19):2004-2005, 2018. e-Pub 2018. PMID: 29746223.
Jiang XE, Xu T, Wei Q, Li P, Gomez DR, Court LE, Liao Z. DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non-small-cell lung cancer. Chronic Dis Transl Med 4(2):109-116, 2018. e-Pub 2018. PMID: 29988954.
Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Komaki R, Hu Y, Hahn SM, Liao Z. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med 7(6):2247-2255, 2018. e-Pub 2018. PMID: 29745043.
Zhang Y, Lin Q, Xu T, Deng W, Yu J, Liao Z, Yue J. Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. Cancer Lett 421:59-62, 2018. e-Pub 2018. PMID: 29425685.
Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys 100(3):730-737, 2018. e-Pub 2018. PMID: 29248169.
Milbury K, Engle R, Tsao A, Liao Z, Owens A, Chaoul A, Bruera E, Cohen L. Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients with Metastatic Non-Small Cell Lung Cancer and Their Partners. J Pain Symptom Manage 55(3):953-961, 2018. e-Pub 2018. PMID: 29208478.
Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. e-Pub 2018. PMID: 29549533.
Lopez Guerra JL, Song YP, Nguyen QN, Gomez DR, Liao Z, Xu T. Functional promoter rs189037 variant of ATM is associated with decrease in lung diffusing capacity after irradiation for non-small-cell lung cancer. Chronic Dis Transl Med 4(1):59-66, 2018. e-Pub 2018. PMID: 29756124.
Zhou R, Xu T, Nguyen QN, Liu Y, Yang J, Komaki R, Gomez DR, Liao Z. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 100(2):452-461, 2018. e-Pub 2018. PMID: 29174428.
Liu C, Schild SE, Chang JY, Liao Z, Korte S, Shen J, Ding X, Hu Y, Kang Y, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2018. PMID: 29550033.
Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z, Xu T, Gomez DR, Komaki R, Liao Z, Wei Q. Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy. J Thorac Oncol. e-Pub 2018. PMID: 29454863.
Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol 8(1):58-65, 2018. e-Pub 2018. PMID: 28867546.
Hong J, Liao Z, Zhuang Y, Levy LB, Sheu T, Heymach JV, Nguyen QN, Xu T, Komaki R, Gomez DR. Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis. Am J Clin Oncol 41(1):46-52, 2018. e-Pub 2018. PMID: 26535988.
Shusharina N, Liao Z, Mohan R, Liu A, Niemierko A, Choi N, Bortfeld T. Differences in lung injury after IMRT or proton therapy assessed by 18FDG PET imaging. Radiother Oncol. e-Pub 2018. PMID: 29352608.
Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol:JCO2017740720. e-Pub 2018. PMID: 29293386.
Milbury K, Tsao AS, Liao Z, Owns A, Engle R, Gonzalez EA, Bruera E, Cohen L. A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. Pilot Feasibility Stud 4:37, 2018. e-Pub 2018. PMID: 29416870.
Tang C, Lee MS, Gomez DR, Levy LB, Zhuang Y, Lu C, Liao Z, Komaki R. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol 40(6):625-630, 2017. e-Pub 2017. PMID: 26165417.
Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez DR. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol 125(2):325-330, 2017. e-Pub 2017. PMID: 29054376.
Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. FDG-PET Response After Induction Chemotherapy Can Predict Who Will Benefit From Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 58(11):1756-1763, 2017. e-Pub 2017. PMID: 28522744.
Yang J, Haas B, Fang R, Beadle BM, Garden AS, Liao Z, Zhang L, Balter P, Court L. Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. Phys Med Biol 62(23):9140-9158, 2017. e-Pub 2017. PMID: 29049027.
Niedzielski JS, Yang J, Mohan R, Titt U, Mirkovic D, Stingo F, Liao Z, Gomez DR, Martel MK, Briere TM, Court LE. Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In Vivo Imaging Biomarkers. Int J Radiat Oncol Biol Phys 99(4):1013-1020, 2017. e-Pub 2017. PMID: 29063837.
Xu Y, Deng W, Yang S, Li P, Kong Y, Tian Y, Liao Z, Chen M. Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer. Sci Rep 7(1):14863, 2017. e-Pub 2017. PMID: 29093491.
Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin Cancer Res 23(19):5948-5958, 2017. e-Pub 2017. PMID: 28679765.
Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 99(2):407-416, 2017. e-Pub 2017. PMID: 28871991.
Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 99(1):70-79, 2017. e-Pub 2017. PMID: 28816165.
Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol 3(8). e-Pub 2017. PMID: 28727865.
Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 124(2):318-324, 2017. e-Pub 2017. PMID: 28687396.
Milbury K, Kavanagh A, Meng Z, Chen Z, Chandwani KD, Garcia K, Perkins GH, McQuade J, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer 25(7):2103-2109, 2017. e-Pub 2017. PMID: 28233122.
Niedzielski JS, Yang J, Stingo F, Liao Z, Gomez DR, Mohan R, Martel M, Briere T, Court L. A Novel Methodology using CT Imaging Biomarkers to Quantify Radiation Sensitivity in the Esophagus with Application to Clinical Trials. Scientific Reports 7(1):6034, 2017. e-Pub 2017.
Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Int J Radiat Oncol Biol Phys 98(4):820-828, 2017. e-Pub 2017. PMID: 28476435.
Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. e-Pub 2017. PMID: 28744603.
Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(4):900-907, 2017. e-Pub 2017. PMID: 28258887.
Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol 123(3):376-381, 2017. e-Pub 2017. PMID: 28455153.
Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol 12(6):983-92. e-Pub 2017. PMID: 28259750.
Yue J, McKeever M, Sio TT, XUT, Huo J, Shi Q, Nguyen QN, Komaki R, Gomez DR, Pan T, Wang XS, Liao Z. Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer. Clin Transl Radiat Oncol. e-Pub 2017.
Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg, 2017. e-Pub 2017. PMID: 28628563.
Chi A, Chen H, Wen S, Yan H, Liao Z. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. Radiother Oncol 123(3):346-354, 2017. e-Pub 2017. PMID: 28545956.
Nguyen QN, Lu Y, Tang C, Chance WW, Mehran R, Balter P, Welsh JW, Hahn SM, Jeter MD, Komaki RU, Gomez DR, Chang JY, Liao Z. Stereotactic Ablative Body Radiation for Pulmonary Metastases: Should We Consider Dose Escalation for More Unresponsive Histologies?. Int J Radiat Oncol Biol Phys 98(1):237, 2017. e-Pub 2017. PMID: 28587012.
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez DR, Followill D, Jones AK, Stingo F, Mohan R, Liao Z, Court LE. Using Pretreatment Radiomics and Delta-Radiomics Features to Predict Non-Small Cell Lung Cancer Patient Outcomes. Int J Radiat Oncol Biol Phys 98(1):249, 2017. e-Pub 2017. PMID: 28587041.
Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Hahn S, Liao Z. Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. Oncotarget 8(26):43080-43090, 2017. e-Pub 2017. PMID: 28574846.
Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Zhu XR, Gomez DR, Lin SH, Gillin MT, Komaki RU, Liao Z, Hahn SM, Chang JY. Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy. Int J Radiat Oncol Biol Phys 98(1):222, 2017. e-Pub 2017. PMID: 28586972.
Yang J, Xu T, Gomez DR, Jeter M, Levy LB, Song Y, Hahn S, Liao Z, Yuan X. The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy. Transl Oncol 10(2):197-202, 2017. e-Pub 2017. PMID: 28189065.
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez D, Followill D, Jones AK, Stingo F, Liao Z, Mohan R, Court L. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep 7(1):588, 2017. e-Pub 2017. PMID: 28373718.
Fang P, Swanick CW, Pezzi TA, Liao Z, Welsh J, Lin SH, Gomez DR. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. e-Pub 2017. PMID: 28428017.
Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 123(16):3031-3039. e-Pub 2017. PMID: 28346656.
Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. e-Pub 2017. PMID: 28244413.
Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol. e-Pub 2017. PMID: 28351804.
Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small-Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. e-Pub 2017. PMID: 28259750.
Chun SG, Solberg TD, Grosshans DR, Nguyen QN, Simone CB, Mohan R, Liao Z, Hahn SM, Herman JM, Frank SJ. The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer. Front Oncol 7:201, 2017. e-Pub 2017. PMID: 28929085.
Zhou R, Liao Z, Pan T, Milgrom SA, Pinnix CC, Shi A, Tang L, Yang J, Liu Y, Gomez D, Nguyen QN, Dabaja BS, Court L, Yang J. Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiother Oncol. e-Pub 2016. PMID: 27939201.
Niedzielski JS, Yang J, Liao Z, Gomez DR, Stingo F, Mohan R, Martel MK, Briere TM, Court LE. (18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. Int J Radiat Oncol Biol Phys 96(3):670-8, 2016. e-Pub 2016. PMID: 27681764.
Reddy JP, Tang C, Shih T, Kim B, Kim C, Nguyen QN, Welsh J, Benveniste M, Zhang J, Liao Z, Gomez DR. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clin Lung Cancer. e-Pub 2016. PMID: 27913215.
He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol 121(1):70-74, 2016. e-Pub 2016. PMID: 27562616.
Briere TM, Krafft S, Liao Z, Martel MK. In Reply to Jin et al. Int J Radiat Oncol Biol Phys 96(2):481-2, 2016. e-Pub 2016. PMID: 27598813.
Lu Q, You J, Kavanagh A, Warmoth K, Meng Z, Chen Z, Chandwani KD, Perkins GH, McQuade JL, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer 24(9):3775-82, 2016. e-Pub 2016. PMID: 27048455.
Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY. Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. e-Pub 2016. PMID: 27743801.
Tang C, Liao Z, Hess K, Chance WW, Zhuang Y, Jensen G, Xu T, Komaki R, Gomez DR. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncol 55(8):1022-8, 2016. e-Pub 2016. PMID: 27055359.
Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single nucleotide polymorphisms in CBLB, a regulator of T-cell response, predict radiation pneumonitis and outcomes after definitive radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 17(4):253-262.e5, 2016. e-Pub 2016. PMID: 26732495.
Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, Liao Z, Grosshans D. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 119(3):495-500, 2016. e-Pub 2016. PMID: 27189523.
Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Factors predictive of improved outcomes with multimodality local therapy after palliative chemotherapy for stage iv esophageal cancer. Am J Clin Oncol 39(3):228-35, 2016. e-Pub 2016. PMID: 24710122.
Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage 51(5):832-8, 2016. e-Pub 2016. PMID: 26891607.
Liu W, Schild SE, Chang JY, Liao Z, Chang YH, Wen Z, Shen J, Stoker JB, Ding X, Hu Y, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, Bues M. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. Int J Radiat Oncol Biol Phys 95(1):523-33, 2016. e-Pub 2016. PMID: 26725727.
Hunter LA, Chen YP, Zhang L, Matney JE, Choi H, Kry SF, Martel MK, Stingo F, Liao Z, Gomez D, Yang J, Court LE. NSCLC tumor shrinkage prediction using quantitative image features. Comput Med Imaging Graph 49:29-36, 2016. e-Pub 2016. PMID: 26878137.
Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, Komaki R, Ho L, Hofstetter WL, Swisher SG, Mehran RJ, Buchholz TA, Elting LS, Giordano SH. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 122(6):917-28, 2016. e-Pub 2016. PMID: 26716915.
Niedzielski JS, Yang J, Stingo F, Martel MK, Mohan R, Gomez DR, Briere TM, Liao Z, Court LE. Objectively quantifying radiation esophagitis with novel computed tomography-based metrics. Int J Radiat Oncol Biol Phys 94(2):385-93, 2016. e-Pub 2016. PMID: 26675063.
Fried DV, Mawlawi O, Zhang L, Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Potential Use of (18)F-fluorodeoxyglucose Positron Emission Tomography-Based Quantitative Imaging Features for Guiding Dose Escalation in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 94(2):368-76, 2016. e-Pub 2016. PMID: 26853345.
Briere TM, Krafft S, Liao Z, Martel MK. Lung size and the risk of radiation pneumonitis. Int J Radiat Oncol Biol Phys 94(2):377-84, 2016. e-Pub 2016. PMID: 26675062.
Fried DV, Mawlawi O, Zhang L, Fave X, Zhou S, Ibbott G, Liao Z, Court LE. Stage III non-small cell lung cancer: prognostic value of FDG PET quantitative imaging features combined with clinical prognostic factors. Radiology 278(1):377-84, 2016. e-Pub 2016. PMID: 26176655.
Milbury K, Mallaiah S, Lopez G, Liao Z, Yang C, Carmack C, Chaoul A, Spelman A, Cohen L. Vivekananda yoga program for patients with advanced lung cancer and their family caregivers. Integr Cancer Ther 14(5):446-51, 2015. e-Pub 2015. PMID: 25917816.
Rubinstein AE, Liao Z Melancon AD, Guindani M, Followill DS, Tailor RC, Hazle JD, Court LE. Technical note: a monte carlo study of magnetic-field-induced radiation dose effects in mice. Med Phys 42(9):5510-6, 2015. e-Pub 2015. PMID: 26328998.
Pan HY, Jiang S, Sutton J, Liao Z, Chance WW, Frank SJ, Zhu XR, Li H, Fontanilla HP, Zhang X, Gomez DR. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series. Pract Radiat Oncol 5(4):e345-53, 2015. e-Pub 2015. PMID: 25572666.
Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol 115(3):367-72, 2015. e-Pub 2015. PMID: 26028228.
Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol 10(3):518-26, 2015. e-Pub 2015. PMID: 25695222.
Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16(2):156-163, 2015. e-Pub 2015. PMID: 25467928.
Li H, Zhang X, Park P, Liu W, Chang J, Liao Z, Frank S, Li Y, Poenisch F, Mohan R, Gillin M, Zhu R. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol 114(3):367-72, 2015. e-Pub 2015. PMID: 25708992.
Liu W, Liao Z, Schild SE, Liu Z, Li H, Li Y, Park PC, Li X, Stoker J, Shen J, Keole S, Anand A, Fatyga M, Dong L, Sahoo N, Vora S, Wong W, Zhu XR, Bues M, Mohan R. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol 5(2):e77-86, 2015. e-Pub 2015. PMID: 25413400.
Wang H, Liao Z, Zhuang Y, Liu Y, Levy LB, Xu T, Yusuf SW, Gomez DR. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin Lung Cancer 16(2):128-136, 2015. e-Pub 2015. PMID: 25450873.
Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 6(1):45-52, 2015. e-Pub 2015. PMID: 25642337.
Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91(1):149-56, 2015. e-Pub 2015. PMID: 25442335.
Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-84, 2014. e-Pub 2014. PMID: 25466375.
Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, Court LE. Prognostic value and reproducibility of pretreatment CT texture features in stage iii non-small cell lung cancer. Int J Radiat Oncol Biol Phys 90(4):834-842, 2014. e-Pub 2014. PMID: 25220716.
McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys 90(4):819-827, 2014. e-Pub 2014. PMID: 25220718.
Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys 90(4):809-818, 2014. e-Pub 2014. PMID: 25260491.
Kardar L, Li Y, Li X, Li H, Cao W, Chang JY, Liao Z, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol 4(6):E259-268, 2014. e-Pub 2014. PMID: 25407877.
Sheu T, Heymach JV, Swisher SG, Rao G, Weinberg JS, Mehran R, McAleer MF, Liao Z, Aloia TA, Gomez DR. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys 90(4):850-857, 2014. e-Pub 2014. PMID: 25216859.
Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1554-1560, 2014. e-Pub 2014. PMID: 25521400.
He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 9(9):1398-1405, 2014. e-Pub 2014. PMID: 25122435.
Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. e-Pub 2014. PMID: 25108807.
Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5):1084-1091, 2014. e-Pub 2014. PMID: 25035212.
Rosenstein BS, West CM, Bentzen SM, Alsner J, Andreassen CN, Azria D, Barnett GC, Baumann M, Burnet N, Chang-Claude J, Chuang EY, Coles CE, Dekker A, De Ruyck K, De Ruysscher D, Drumea K, Dunning AM, Easton D, Eeles R, Fachal L, Gutiérrez-Enríquez S, Haustermans K, Henríquez-Hernández LA, Imai T, Jones GD, Kerns SL, Liao Z, Onel K, Ostrer H, Parliament M, Pharoah PD, Rebbeck TR, Talbot CJ, Thierens H, Vega A, Witte JS, Wong P, Zenhausern F, Consortium R. Radiogenomics: radiobiology enters the era of big data and team science. Int J Radiat Oncol Biol Phys 89(4):709-713, 2014. e-Pub 2014. PMID: 24969789.
Wen J, Liu H, Wang Q, Liu Z, Li Y, Xiong H, Xu T, Li P, Wang LE, Gomez DR, Mohan R, Komaki R, Liao Z, Wei Q. Genetic variants of the Lin28b gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer 50(10):1706-1716, 2014. e-Pub 2014. PMID: 24780874.
Tucker SL, Liao Z, Dinh J, Bian SX, Mohan R, Martel MK, Grosshans DR. Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort. Acta Oncol 53(5):590-596, 2014. e-Pub 2014. PMID: 23992110.
Chaoul A, Milbury K, Engle R, Liao Z, Yang C, Carmack C, Shannon V, Spelman A, Wangyal T, Cohen L. Tibetan yoga can help people with lung cancer and their caregivers. J Altern Complement Med 20(5):A52, 2014. e-Pub 2014. PMID: 24805634.
Juloori A, Tucker SL, Komaki R, Liao Z, Correa AM, Swisher SG, Hofstetter WL, Lin SH. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol 9(4):534-540, 2014. e-Pub 2014. PMID: 24736077.
Tang C, Liao Z, Zhuang Y, Levy LB, Hung C, Li X, Krafft SP, Martel MK, Komaki R, Gomez DR. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol 110(3):493-498, 2014. e-Pub 2014. PMID: 24560756.
Tang C, Gomez DR, Wang H, Levy LB, Zhuang Y, Xu T, Nguyen Q, Komaki R, Liao Z. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88(2):319-325, 2014. e-Pub 2014. PMID: 24411603.
Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao Z, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys 41(2):021721, 2014. e-Pub 2014. PMID: 24506612.
Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus 27(2):168-175, 2014. e-Pub 2014. PMID: 23621168.
Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol 21(1):306-314, 2014. e-Pub 2014. PMID: 24197760.
Li H, Park P, Liu W, Matney J, Liao Z, Balter P, Li Y, Zhang X, Li X, Zhu XR. Patient-specific quantification of respiratory motion-induced dose uncertainty for step-and-shoot IMRT of lung cancer. Med Phys 40(12):121712, 2013. e-Pub 2013. PMID: 24320498.
Matney J, Park PC, Bluett J, Chen YP, Liu W, Court LE, Liao Z, Li H, Mohan R. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion?. Int J Radiat Oncol Biol Phys 87(3):576-582, 2013. e-Pub 2013. PMID: 24074932.
Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 24(11):2844-9, 2013. e-Pub 2013. PMID: 23975663.
Li Q, Yang J, Yu Q, Wu H, Liu B, Xiong H, Hu G, Zhao J, Yuan X, Liao Z. Associations between single nucleotide polymorphisms in the PI3K/PTEN/AKT/mTOR pathway and increased risk of brain metastasis in patients with non-small-cell lung cancer. Clin Cancer Res 19(22):6252-6260, 2013. e-Pub 2013. PMID: 24077347.
Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, Zhu G, Lu Y, Han C, Zhu S, Liao Z, Yu J. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail. Radiother Oncol. e-Pub 2013. PMID: 24128808.
Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly M, Gold KA, Gomez DR. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 24161424.
Yang J, Amini A, Williamson R, Zhang L, Zhang Y, Komaki R, Liao Z, Cox J, Welsh J, Court L, Dong L. Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiotherapy. Pract Radiat Oncol 3(4), 2013. e-Pub 2013. PMID: 24273627.
McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. e-Pub 2013. PMID: 24016675.
Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 2013. e-Pub 2013. PMID: 23920393.
Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 86(5):885-91, 2013. e-Pub 2013. PMID: 23845841.
Niedzielski J, Bluett JB, Williamson RT, Liao Z, Gomez DR, Court LE. Analysis of esophageal-sparing treatment plans for patients with high-grade esophagitis. J Appl Clin Med Phys 14(4):4248, 2013. e-Pub 2013. PMID: 23835390.
Chen J, Pan J, Liu J, Li J, Zhu K, Zheng X, Chen M, Chen M, Liao Z. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 86(4):671-7, 2013. e-Pub 2013. PMID: 23773390.
Vinogradskiy Y, Castillo R, Castillo E, Tucker SL, Liao Z, Guerrero T, Martel MK. Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. Int J Radiat Oncol Biol Phys 86(2):366-71, 2013. e-Pub 2013. PMID: 23474113.
Wang H, Gomez DR, Liao Z. β-Blockers and metastasis in non-small-cell lung cancer. Expert Rev Anticancer Ther 13(6):641-3, 2013. e-Pub 2013. PMID: 23773098.
Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 23688815.
Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. Balancing radiation pneumonitis versus locoregional tumor control in non-small-cell lung cancer. J Thorac Oncol 8(5):e47-8, 2013. e-Pub 2013. PMID: 23584304.
Wang HM, Liao Z, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-9, 2013. e-Pub 2013. PMID: 23300016.
Chen Z, Meng Z, Milbury K, Bei W, Zhang Y, Thornton B, Liao Z, Wei Q, Chen J, Guo X, Liu L, McQuade J, Kirschbaum C, Cohen L. Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer 119(9):1690-8, 2013. e-Pub 2013. PMID: 23355182.
Chi A, Wen S, Nguyen NP, Jacobson G, Remick S, Tse W, Liao Z. Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma. Chin J Cancer Res 25(2):128-9, 2013. e-Pub 2013. PMID: 23592890.
Pang Q, Wei Q, Yuan X, Lopez Guerra JL, Levy LB, Liu Z, Gomez DR, Zhuang Y, Wang LE, Mohan R, Komaki R, Liao Z. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 85(5):1332-9, 2013. e-Pub 2013. PMID: 23374503.
Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31(7):895-902, 2013. e-Pub 2013. PMID: 23341526.
Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-45, 2013. e-Pub 2013. PMID: 23247629.
Tucker SL, Mohan R, Liengsawangwong R, Martel MK, Liao Z. Predicting pneumonitis risk: a dosimetric alternative to mean lung dose. Int J Radiat Oncol Biol Phys 85(2):522-7, 2013. e-Pub 2013. PMID: 22580121.
Hunter NR, Valdecanas D, Liao Z, Milas L, Thames HD, Mason KA. Mitigation and treatment of radiation-induced thoracic injury with a cyclooxygenase-2 Inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 85(2):472-6, 2013. e-Pub 2013. PMID: 22672748.
Tucker SL, Li M, Xu T, Gomez D, Yuan X, Yu J, Liu Z, Yin M, Guan X, Wang LE, Wei Q, Mohan R, Vinogradskiy Y, Martel M, Liao Z. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys 85(1):251-7, 2013. e-Pub 2013. PMID: 22541966.
Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24(1):67-74, 2013. e-Pub 2013. PMID: 23002278.
Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, Mendoza TR. Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Qual Life Res. e-Pub 2013. PMID: 23371797.
Court LE, Tucker SL, Gomez D, Liao Z, Zhang J, Kry S, Dong L, Martel MK. A technique to use CT images for in vivo detection and quantification of the spatial distribution of radiation-induced esophagitis. J Appl Clin Med Phys 14(3):4195, 2013. e-Pub 2013. PMID: 23652249.
Chi A, Wen S, Liao Z, Fowler J, Xu J, Nguyen NP, Welsh JS, Komaki R. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int 2013:391021, 2013. e-Pub 2013. PMID: 24350266.
Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 38(4):442-7, 2013. e-Pub 2013. PMID: 24200220.
Yuan X, Wei Q, Komaki R, Liu Z, Yang J, Tucker SL, Xu T, Heymach JV, Lu C, Cox JD, Liao Z. TGFB1 polymorphisms predict distant metastasis–free survival in patients with inoperable non-small-cell lung cancer after definitive radiotherapy. PLoS One 8(6):e65659, 2013. e-Pub 2013. PMID: 23840350.
Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 84(5):1078-85, 2012. e-Pub 2012. PMID: 22867894.
Guerra JL, Gomez D, Wei Q, Liu Z, Wang LE, Yuan X, Zhuang Y, Komaki R, Liao Z. Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. Radiother Oncol 105(3):299-304, 2012. e-Pub 2012. PMID: 23022171.
Xiong H, Liao Z, Liu Z, Xu T, Wang Q, Liu H, Komaki R, Gomez D, Wang L, Wei Q. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. International Journal of Radiation Oncology, Biology, Physics. e-Pub 2012. PMID: 23154078.
Vinogradskiy Y, Tucker SL, Bluett JB, Wages CA, Liao Z, Martel MK. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol 7(11):1676-82, 2012. e-Pub 2012. PMID: 23059778.
Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Lopez Guerra JL, Liu H, Komaki R, Cox JD, Liao Z. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(4):1010-6, 2012. e-Pub 2012. PMID: 22920974.
Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 gene polymorphisms predict risk of mortality for us patients after radio(chemo)therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(2):e229-35, 2012. e-Pub 2012. PMID: 22608953.
Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys 84(1):e61-7, 2012. e-Pub 2012. PMID: 22503522.
Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated volumetric modulated arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy?. Int J Radiat Oncol Biol Phys 84(1):e69-76, 2012. e-Pub 2012. PMID: 22901421.
Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 9(8):471-478, 2012. e-Pub 2012. PMID: 22751283.
Lopez Guerra JL, Gomez D, Zhuang Y, Levy LB, Eapen G, Liu H, Mohan R, Komaki R, Cox JD, Liao Z. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83(5):1573-9, 2012. e-Pub 2012. PMID: 22768989.
Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-51, 2012. e-Pub 2012. PMID: 22417808.
Lopez Guerra JL, Gomez DR, Zhuang Y, Levy LB, Eapen G, Liu H, Mohan R, Komaki R, Cox JD, Liao Z. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83(4):e537-43, 2012. e-Pub 2012. PMID: 22420964.
Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-r1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 2012. e-Pub 2012. PMID: 22251605.
Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-9, 2012. e-Pub 2012. PMID: 22436793.
Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z. Long term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the md anderson experience. Int J Radiat Oncol Biol Phys 83(1):332-9, 2012. e-Pub 2012. PMID: 22079735.
Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-40, 2012. e-Pub 2012. PMID: 22565611.
Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-50, 2012. e-Pub 2012. PMID: 22320189.
Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys 82(5):1650-8, 2012. e-Pub 2012. PMID: 21497454.
Amini A, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox J, Dong L, Welsh J. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 82(3):e391-8, 2012. e-Pub 2012. PMID: 22284035.
Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. A novel method to incorporate the spatial location of the lung dose distribution into predictive radiation pneumonitis modeling. Int J Radiat Oncol Biol Phys 82(4):1549-55, 2012. e-Pub 2012. PMID: 21741183.
Lopez Guerra JL, Gladish G, Komaki R, Gomez D, Zhuang Y, Liao Z. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med 53(2):225-33, 2012. e-Pub 2012. PMID: 22241911.
Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer 118(2):528-35, 2012. e-Pub 2012. PMID: 21717429.
Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82(1):468-74, 2012. e-Pub 2012. PMID: 21123005.
Chen J, Pan J, Zheng X, Zhu K, Li J, Chen M, Wang J, Liao Z. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 82(1):475-82, 2012. e-Pub 2012. PMID: 20934269.
Chi A, Liao Z, Nguyen NP, Xu J, Welsh JS, Jang SY, Howe C, Komaki R. Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. PLoS One 7(4):e35809, 2012. e-Pub 2012. PMID: 22558228.
Li Q, Wu H, Chen B, Hu G, Huang L, Qin K, Chen Y, Yuan X, Liao Z. SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer. PLoS One 7(12):e51713, 2012. e-Pub 2012. PMID: 23284751.
Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7:152, 2012. e-Pub 2012. PMID: 22963661.
Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81(5):1336-42, 2011. e-Pub 2011. PMID: 21470796.
Lopez Guerra JL, Wei Q, Yuan X, Gomez D, Liu Z, Zhuang Y, Yin M, Li M, Wang LE, Cox JD, Liao Z. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non–small cell lung cancer treated with radio(chemo)therapy. Radiother Oncol 101((2)):271-7, 2011. e-Pub 2011. PMID: 21937138.
Yin M, Liao Z, Liu Z, Wang LE, Gomez D, Komaki R, Wei Q. Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 81(3):e67-73, 2011. e-Pub 2011. PMID: 21420246.
Liao Z, Lin SH, Cox JD. Status of particle therapy for lung cancer. Acta Oncology 50(6):745-56, 2011. e-Pub 2011. PMID: 21767170.
Wang L, Raju U, Milas L, Molkentine D, Zhang Z, Yang P, Cohen L, Meng Z, Liao Z. Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Res 31(6):2141-8, 2011. e-Pub 2011. PMID: 21737634.
Chi A, Liao Z, Nguyen NP, Howe C, Gomez D, Jang SY, Komaki R. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol 6(6):1132-41, 2011. e-Pub 2011. PMID: 21532502.
Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. e-Pub 2011. PMID: 21365188.
Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the m. d. anderson symptom inventory. Oncologist. e-Pub 2011. PMID: 21285393.
Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 79(2):473-80, 2011. e-Pub 2011. PMID: 20399032.
Ouyang H, Wang P, Meng Z, Chen Z, Yu E, Jin H, Chang DZ, Liao Z, Cohen L, Liu L. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or chinese herbal medicine. Pancreas 40(1):120-5, 2011. e-Pub 2011. PMID: 20683216.
Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for non-small cell lung cancer. Cancer. e-Pub 2011. PMID: 21264827.
Yin M, Liao Z, Huang YJ, Liu Z, Yuan X, Gomez D, Wang LE, Wei Q. Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One 6(5):e20055, 2011. e-Pub 2011. PMID: 21647442.
Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 1:52, 2011. e-Pub 2011. PMID: 22649768.
Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78(5):1387-93, 2010. e-Pub 2010. PMID: 20381271.
Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 116(19):4487-94, 2010. e-Pub 2010. PMID: 20629031.
Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 90(3):892-8; discussion 898-9, 2010. e-Pub 2010. PMID: 20732514.
Chen J, Zhu J, Pan J, Zhu K, Zheng X, Chen M, Wang J, Liao Z. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus. Ann Thorac Surg 90(2):435-42, 2010. e-Pub 2010. PMID: 20667325.
Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968-74, 2010. e-Pub 2010. PMID: 20353817.
Tucker SL, Jin H, Wei X, Wang S, Martel MK, Komaki R, Liu HH, Mohan R, Chen Y, Cox JD, Liao Z. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 77(3):691-698, 2010. e-Pub 2010. PMID: 19836159.
Liao Z, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76(3):775-81, 2010. e-Pub 2010. PMID: 19515503.
Meng ZQ, Garcia MK, Chiang JS, Peng HT, Shi YQ, Fu J, Liu LM, Liao Z, Zhang Y, Bei WY, Thornton B, Palmer JL, McQuade J, Cohen L. Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial. World J Gastroenterol 16(1):104-111, 2010. e-Pub 2010.
Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluoro-deoxy-glucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 78(5-6):316-22, 2010. e-Pub 2010. PMID: 20699623.
Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8), 2010. e-Pub 2010. PMID: 20811626.
Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10:431, 2010. e-Pub 2010. PMID: 20712888.
Cen P, Correa AM, Lee JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus 22(1):32-41, 2009. e-Pub 2009. PMID: 19021684.
Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 115(22):5184-92, 2009. e-Pub 2009. PMID: 19685531.
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer 115(22):5309-5318, 2009. e-Pub 2009.
Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q. Single nucleotide polymorphism at rs1982073:t869c of the TGF{beta}1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 27(20):3370-3378, 2009. e-Pub 2009. PMID: 19380441.
McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for non-small cell lung cancer?. Cancer 115(14):3233-3242, 2009. e-Pub 2009. PMID: 19472405.
Zhang Z, Chen Y, Chen YZ, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Guerrero TM, Allen PK, Cox JD, Komaki R, Liao Z. Outcomes with esophageal cancer radiation therapy. J Thor Oncol 4(7):880-888, 2009. e-Pub 2009. PMID: 19458557.
Jin H, Tucker SL, Liu HH, Wei X, Yom SS, Wang S, Komaki R, Chen Y, Martel MK, Mohan R, Cox JD, Liao Z. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol 91(3):427-432, 2009. e-Pub 2009. PMID: 18937989.
Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: the seer-medicare cohort. Int J Radiat Oncol Biol Phys 74(2):482-489, 2009. e-Pub 2009. PMID: 19289262.
Gayed I, Gohar S, Liao Z, McAleer M, Bassett R, Yusuf SW. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging 25(5):487-495, 2009. e-Pub 2009. PMID: 19234869.
Pan X, Zhang X, Li Y, Mohan R, Liao Z. Impact of using different 4D CT data sets to design proton treatment plans for distal esophageal cancer. Int J Radiat Oncol Biol Phys 73(2):601-609, 2009. e-Pub 2009. PMID: 19147024.
Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 4(2):179-184, 2009. e-Pub 2009. PMID: 19179893.
Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):119-127, 2009. e-Pub 2009. PMID: 18556142.
Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967-971, 2008. e-Pub 2008. PMID: 18954709.
Tucker SL, Liu HH, Liao Z, Wei X, Wang S, Jin H, Komaki R, Martel MK, Mohan R. Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys 72(2):568-574, 2008. e-Pub 2008. PMID: 18793959.
Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, Cox JD, Hui Z, Li Y, Newhauser WD, Mohan R, Liao Z. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72(1):278-287, 2008. e-Pub 2008. PMID: 18722278.
Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 113(6):1302-1308, 2008. e-Pub 2008. PMID: 18623381.
Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-864, 2008. e-Pub 2008.
Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 71(3):890-899, 2008. e-Pub 2008. PMID: 18514781.
Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26(28):4551-4556, 2008. e-Pub 2008. PMID: 18574157.
Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277-82, 2008. e-Pub 2008. PMID: 18317071.
Wei X, Liu HH, Tucker SL, Wangs, Mohan R, Cox JD, Komaki R, Liao Z. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70(3):707-714, 2008. e-Pub 2008. PMID: 18191334.
Yaremko BP, Guerrero TM, McAleer MF, Bucci MK, Martinez JN, Nguyen LT, Balter PA, Guerra R, Komaki R, Liao Z. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 70(1):145-153, 2008. e-Pub 2008. PMID: 17855008.
Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127-132, 2008. e-Pub 2008. PMID: 19021681.
Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685-1692; discussion 1692-1693, 2007. e-Pub 2007. PMID: 17954086.
Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-357, 2007. e-Pub 2007. PMID: 17467922.
Zhao KL, Liao Z, Bucci MK, Komaki R, Cox JD, Yu ZH, Zhang L, Mohan R, Dong L. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol 84(3):283-289, 2007. e-Pub 2007. PMID: 17716759.
Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68(5):1349-1358, 2007. e-Pub 2007. PMID: 17446001.
Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 84(2):365-373; discussion 374-375, 2007. e-Pub 2007. PMID: 17643602.
Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-785, 2007. e-Pub 2007. PMID: 17418967.
Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, Liao Z, Ajani J, Stevens C, Komaki R. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys 68(4):1030-1035, 2007. e-Pub 2007. PMID: 17398033.
Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang J, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 68(2):531-540, 2007. e-Pub 2007. PMID: 17398035.
Davidson SE, Ibbott GS, Prado KL, Dong L, Liao Z, Followill DS. Accuracy of two heterogeneity dose calculation algorithms for IMRT in treatment plans designed using an anthropomorphic thorax phantom. Med Phys 34(5):1850-1857, 2007. e-Pub 2007. PMID: 17555266.
Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68(1):94-102, 2007. e-Pub 2007. PMID: 17321067.
Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 67(3):906-914, 2007. e-Pub 2007. PMID: 17293240.
Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66(5):1399-1407, 2006. e-Pub 2006.
Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47(11):1756-1762, 2006. e-Pub 2006. PMID: 17079807.
Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12(21):6565-6572, 2006. e-Pub 2006. PMID: 17085672.
Hui Z, Li Y, Yu Z, Liao Z. Survey on use of postmastectomy radiotherapy for breast cancer in China. Int J Radiat Oncol Biol Phys 66(4):1135-1142, 2006. e-Pub 2006.
Tucker SL, Liu HH, Wang S, Wei X, Liao Z, Komaki R, Cox JD, Mohan R. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66(3):754-761, 2006. e-Pub 2006. PMID: 16965865.
Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5(11):2844-2850, 2006. e-Pub 2006. PMID: 17121931.
Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33(10):3931-3938, 2006. e-Pub 2006. PMID: 17089855.
Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66(1):100-107, 2006. e-Pub 2006. PMID: 16839700.
Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 12(34):5501-5508, 2006. e-Pub 2006. PMID: 17006988.
Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24(27):4485-4491, 2006. e-Pub 2006. PMID: 16983118.
Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-3798, 2006. e-Pub 2006. PMID: 16785472.
Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1(5):478-486, 2006. e-Pub 2006. PMID: 17409902.
Hu C, Chang EL, Hassenbusch SJ, Allen PK, Woo SY, Mahajan A, Komaki R, Liao Z. Non-small cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106(9):1998-2004, 2006. e-Pub 2006.
Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106(5):1017-25, 2006. e-Pub 2006. PMID: 16456809.
Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu HH, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64(3):692-699, 2006. e-Pub 2006.
Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 64(3):700-708, 2006. e-Pub 2006. PMID: 16242255.
Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani A, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at neck and upper thorax treated with concurrent chemoradiation - a single institutional experience at M. D. Anderson Cancer Center. J Thorac Oncol 1(3):252-259, 2006. e-Pub 2006.
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106(3):552-558, 2006. e-Pub 2006. PMID: 16353210.
Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24(5):748-754, 2006. e-Pub 2006. PMID: 16401681.
Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 131(1):65-72, 2006. e-Pub 2006. PMID: 16399296.
Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus 19(3):152-157, 2006. e-Pub 2006. PMID: 16722991.
Liu HH, Guerrero T, Liao Z, Tucker S, Wang X, Bonnen M, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R, Stevens C, Chandra A. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77(3):247-253, 2005. e-Pub 2005.
Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104(11):2365-2372, 2005. e-Pub 2005.
Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77(3):247-253, 2005. e-Pub 2005.
Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lynch PM, Rice DC, Roth JA, Ajaini JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-1355, 2005. e-Pub 2005.
Wang SL, Liao Z, Liu XF, Yu ZH, Gu DZ, Qian TN, Song YW, Jin J, Wang WH, Li YX. Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients. World J Gastroenterol 11(37):5905-5909, 2005. e-Pub 2005. PMID: 16270408.
Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-6, 2005. e-Pub 2005. PMID: 16118804.
Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liy HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-1487, 2005. e-Pub 2005.
Zhu XR, Prado K, Liu HH, Guerrero T, Jeter M, Liao Z, Rice D, Foster K, Stevens CW. Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. International Journal of Radiation Oncology, Biology, and Physics 62(5):1525-1534, 2005. e-Pub 2005.
Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki R, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810-817; 817-820, 2005. e-Pub 2005.
Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11(9):3342-8, 2005. e-Pub 2005. PMID: 15867233.
Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11(8):2894-2898, 2005. e-Pub 2005.
Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol 32(2 Suppl 3):S92-8, 2005. e-Pub 2005. PMID: 16015542.
Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. International Journal of Radiation Oncology, Biology, and Physics 61(3):656-664, 2005. e-Pub 2005.
Rosen I, Liu H, Childress N, Liao Z. Interactively exploring optimized treatment plans. Int J Radiat Oncol Biol Phys 61(2):570-582, 2005. e-Pub 2005.
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36(2):69-76, 2005. e-Pub 2005. PMID: 16648656.
Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 60(5):1484-93, 2004. e-Pub 2004. PMID: 15590179.
Liu HH, Koch N, Starkschall G, Jacobson M, Forster K, Liao Z, Komaki R, Stevens CW. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume. Int J Radiat Oncol Biol Phys 60(5):1473-83, 2004. e-Pub 2004. PMID: 15590178.
Koch N, Liu HH, Starkschall G, Jacobson M, Forster K, Liao Z, Komaki R, Stevens CW. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part I--correlating internal lung motion with skin fiducial motion. Int J Radiat Oncol Biol Phys 60(5):1459-72, 2004. e-Pub 2004. PMID: 15590177.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnem J, Walsh G, Smythe R, Roth J, Yao J, Allen PK, Cox JD, Komaki R. Induction chemotherapy increased survival of patients with cancer of the esophagus treated with preoperative chemoradiation therapy followed by surgery. International Journal of Radiation Oncology, Biology, and Physics 60(2):427-436, 2004. e-Pub 2004.
Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki R, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. The American Journal 99(7):1258-1266, 2004. e-Pub 2004.
Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clinical Lung Cancer 5(6):340-353, 2004. e-Pub 2004.
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Jr BG, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. International Journal of Radiation Oncology, Biology, and Physics 58(5):1369-1377, 2004. e-Pub 2004.
Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, Guerrero TM, Komaki R, Cox JD, Mohan R. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, and Physics 58(4):1268-1279, 2004. e-Pub 2004.
Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, and Physics 58(4):1258-1267, 2004. e-Pub 2004.
Nakata E, Mason KA, Hunter N, Husain A, Raju U, Liao Z, Ang KK, Milas L. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58(2):369-75, 2004. e-Pub 2004. PMID: 14751505.
Burnett SS, Starkschalla G, Stevens CW, Liao Z. A deformable-model approach to semi-automatic segmentation of CT images demonstrated by application to the spinal canal. Med Phys 31(2):251-263, 2004. e-Pub 2004. PMID: 15000611.
Brooks C, Starkschall G, Famiglietti R, Cox J, Frank S, Komaki R, Liao Z, Stevens C, Forster K. Heterogeneous planning for homogeneous protocols. Medical Dosimetry 29:80-84, 2004. e-Pub 2004.
Taylor NA, Liao Z, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Jr PJ, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. International Journal of Radiation Oncology, Biology, and Physics 58(1):204-212, 2004. e-Pub 2004. PMID: 14697440.
Butler LE, Forster KM, Stevens CW, Bloch C, Liu HH, Tucker SL, Komaki R, Liao Z, Starkschall G. Dosimetric benefits of respiratory gating: a preliminary study. Journal of Applied Clinical Medical Physics 5(1):16-24, 2004. e-Pub 2004.
Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Ajani JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57(5):1317-1322, 2003. e-Pub 2003. PMID: 14630268.
Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9(6):476-484, 2003. e-Pub 2003. PMID: 14740977.
Frank SJ, Forster KM, Stevens CW, Cox JD, Komaki R, Liao Z, Tucker S, Wang X, Steadham RE, Brooks C, Starkschall G. Treatment planning for lung cancer: traditional homogeneous point dose prescription compared with heterogeneity-corrected dose-volume prescription. Int J Radiat Oncol Biol Phys 56(5):1308-1318, 2003. e-Pub 2003. PMID: 12873675.
Taylor NA, Liao Z, Stevens CW, Walsh G, Roth JA, Jr PJ, Fossella F, Allen P, Cox JD, Komaki R. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. International Journal of Radiation Oncology, Biology, and Physics 56(3):616-625, 2003. e-Pub 2003. PMID: 12788166.
Liao Z, Komaki R, Mason KA, Milas L. Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer. Clin Lung Cancer 4(6):356-365, 2003. e-Pub 2003. PMID: 14599301.
Gopal R, Starkschall G, Tucker SL, Cox JD, Liao Z, Hanus M, Kelly JF, Stevens CW, Komaki R. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 56(1):114-120, 2003. e-Pub 2003. PMID: 12694829.
Gopal R, Tucker SL, Komaki R, Liao Z, Forster KM, Stevens C, Kelly JF, Starkschall G. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys 56(1):106-113, 2003. e-Pub 2003. PMID: 12694828.
Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF, Vaporciyan A, Ahamad A, Dong L, Salehpour M, Komaki R, Stevens CW. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. International Journal of Radiation Oncology, Biology, and Physics 55(3):606-616, 2003. e-Pub 2003. PMID: 12573747.
Ahamad A, Stevens CW, Smythe WR, Vaporciyan AA, Komaki R, Kelly JF, Liao Z, Starkschall G, Forster KM. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 55(3):768-775, 2003. e-Pub 2003. PMID: 12573764.
Kaplan B, Stevens CW, Allen P, Liao Z, Komaki R. Outcomes and patterns of failure in bronchial carcinoid tumors. International Journal of Radiation Oncology, Biology, and Physics 55(1):125-131, 2003. e-Pub 2003. PMID: 12504044.
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. e-Pub 2003. PMID: 12538456.
Jin J, Liao Z, Gao L, Huang XD, Xu GZ. Analysis of prognostic factors for T1N0M0 glottic cancer treated with definitive radiotherapy alone: experience of the Cancer Hospital of Peking Union Medical College and the Chinese Academy of Medical Science. International Journal of Radiation Oncology, Biology, and Physics 54(2):471-478, 2002. e-Pub 2002.
Liao Z, Komaki R, Stevens C, Kelly J, Fossella F, Lee JS, Allen P, Cox JD. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53(3):558-565, 2002. e-Pub 2002. PMID: 12062597.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-49, 2002. e-Pub 2002. PMID: 11917284.
Stevens CW, Munden RF, Forster KM, Kelly JF, Liao Z, Starkschall G, Tucker S, Komaki R. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys 51(1):62-68, 2001. e-Pub 2001. PMID: 11516852.
Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 50(4):971-977, 2001. e-Pub 2001. PMID: 11429225.
Komaki R, Cox JD, Putnam Jr JB, Walsh G, Vaporciyan A, Liao Z, Stevens C, Fossella FV, Lee JS, Hong WK, Roth J. The management of superior sulcus tumors. Journal Japanese Society for Therapeutic Radiology and Oncology 13(3):131-138, 2001. e-Pub 2001.
Liao Z, Ha CS, McLaughlin P, Manning JT, Hess M, Cabanillas F, Cox JD. Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. Int J Radiat Oncol Biol Phys 48(2):399-403, 2000. e-Pub 2000. PMID: 10974453.
Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 47(5):1191-1200, 2000. e-Pub 2000. PMID: 10889372.
Liao Z, Ha CS, Fuller LM, Hagemeister FB, Cabanillas F, Tucker SL, Hess MA, Cox JD. Subdiaphragmatic stage I & II hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 41(5):1047-1056, 1998. e-Pub 1998. PMID: 9719114.
Tucker SL, Liao Z, Travis EL. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys 38(5):1055-1066, 1997. e-Pub 1997. PMID: 9276372.
Travis EL, Liao Z, Tucker SL. Spatial heterogeneity of the volume effect for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys 38(5):1045-1054, 1997. e-Pub 1997. PMID: 9276371.
Liao Z, Travis EL, Tucker SL. Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung. Int J Radiat Oncol Biol Phys 32(5):1359-1370, 1995. e-Pub 1995. PMID: 7635776.
Liao Z, Travis EL. Unilateral nephrectomy 24 hours after bilateral kidney irradiation reduces damage to the function and structure of the remaining kidney. Radiat Res 139(3):290-299, 1994. e-Pub 1994. PMID: 8073111.

Invited Articles

Liao Z, Lin SH, Cox JD. Status of particle therapy for lung cancer. Acta Oncol 50(6):745-56, 2011. e-Pub 2011. PMID: 21767170.
Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?. Drugs 67:821-845, 2007. e-Pub 2007.
Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol 2:553-568, 2007. e-Pub 2007.
Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Wang X, Murshed H, Bonnen M, Garg A, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Mutagen sensitivity (ms) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (nsclc) treated by chemoradiotherapy. Semin Oncol 32 2 Suppl 3:S92-98, 2005. e-Pub 2005.
Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32 Suppl 9:S78-81, 2005. e-Pub 2005.
Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin lung cancer 5:340-352, 2005. e-Pub 2005.
Komaki R, Liao Z, Milas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 31 1 suppl 1:47-53, 2004. e-Pub 2004.
Liao Z, Milas L. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expt Rev Anticancer Therp 4:543-560, 2004. e-Pub 2004.
Liao Z, Milas L, Komaki R, Stevens C, Cox JD. Combination of a cox-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 26:S85-91, 2003. e-Pub 2003.
Cox JD, Schechter NR, Lee AK, Forster K, Stevens CW, K-K A, Komaki R, Liao Z, Milas L. Uncertainties in physical and biological targeting with radiation therapy. Rays 28:211-215, 2003. e-Pub 2003.
Liao Z, Komaki R, Mason K, Milas L. Cyclooxygenase-2 (cox-2) enzyme and its inhibition in lung cancer. Clinical Lung Cancer 4:356-365, 2003. e-Pub 2003.
Milas L, Mason KA, Liao Z, Ang KA. Chemoradiotherapy: emerging treatment improvement strategies. Head & Neck 25:152-167, 2003. e-Pub 2003.
Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. Improvement of radiotherapy or chemoradiotherapy by targeting cox-2 enzyme. Oncology (Huntington) 17 (5 Suppl 5):15-24, 2003. e-Pub 2003.
Komaki R, Liao Z, Forster K, Lee HK, Stevens CW, Cox JD. Target definition and contouring in carcinoma of the lung and esophagus. Rays 28:225-236, 2003. e-Pub 2003.

Abstracts

Mikhail Lette MN, Paez D, Shulman LN, Guckenberger M, Douillard J, Oyen WJG, Giammarile F, Rangarajan V, Ginsberg M, Pellet O, Liao Z, Wahab, MA. Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine. JCO Global Oncology, 2022. e-Pub 2022.
Xu T, Liao Z, Nurieva R. The Role of Therapy-induced Senescence-associated Secretory Phenotype in the Development of Cardio-pulmonary Adverse Events. 104th ARS Annual Meeting, 2022. e-Pub 2022.
Liao Z. Comparison of Severe Toxicities and Survival Between Passive Scattering (PSPT) and Intensity Modulated Protons (IMPT) for NSCLC Patients Treated with Concurrent Chemoradiation, 2020. e-Pub 2020.
Liao Z. Pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer: the voxel-based perspective, 2020. e-Pub 2020.
Xu T, Xu Y, Huo J, Yang P, Gomez DR, Liao Z. Incidental Use of Beta-Blockers, Serum VEGF, and Their Association With Disease Outcome in Patients with Non-Small-Cell Lung Cancer Treated with Definitive Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 98(1):245, 2017. e-Pub 2017. PMID: 28587030.
Lan M, Xu T, Gomez DR, Jeter MD, Nguyen QN, Deng W, Lin SH, Komaki RU, Liao Z. Association Between LGALS3 Gene Polymorphisms and Survival in Non-Small Cell Lung Cancer Patients Treated With Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 98(1):249-250, 2017. e-Pub 2017. PMID: 28587040.
Yang P, Liao Z, Gomez DR, Xu T, Levy LB, Deng W, Yang J, Mohan R. Prospective Study of Marginal Recurrence in Patients with Non-Small Cell Lung Cancer After Proton or Photon Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 98(1):234, 2017. e-Pub 2017. PMID: 28587001.
Deist TM, Yang P, Oberije C, Allen PK, van Wijk Y, Gomez DR, Xu T, Mohan R, Hahn SM, Lambin P, Liao Z. Dosimetric Analysis of Randomized Proton and Photon Plans with Respect to Radiation Toxicity: The Importance of High Dose Regions in Lung and Esophagus. Int J Radiat Oncol Biol Phys 98(1):246, 2017. e-Pub 2017. PMID: 28587033.
Liu W, Schild S, Chang J, Liao Z, Ding X, Hu Y, Shen J, Korte S, Sahoo N, Wong W, Herman M, Bues M. TH-CD-209-05: Impact of Spot Size and Spacing On the Quality of Robustly-Optimized Intensity-Modulated Proton Therapy Plans for Lung Cancer. Med Phys 43(6):3886-3887, 2016. e-Pub 2016. PMID: 28048518.
Fried D, Zhang L, Fave X, Ibbott G, Zhou S, Mawlawi O, Liao Z, Court L. MO-DE-207B-10: Impact of Morphologic Characteristics On Radiomics Features From Contast-Enhanced CT for Primary Lung Tumors. Med Phys 43(6):3706, 2016. e-Pub 2016. PMID: 28048272.
Shusharina N, Liao Z, Mohan R, Choi N, Bortfeld T. SU-C-207A-07: Cumulative 18F-FDG Uptake Histogram Relative to Radiation Dose Volume Histogram of Lung After IMRT Or PSPT and Their Association with Radiation Pneumonitis. Med Phys 43(6):3326, 2016. e-Pub 2016. PMID: 28048445.
Luo Y, Liao Z, Jiang W, Gomez D, Williamson R, Court L, Yang J. TU-H-CAMPUS-JeP2-05: Can Automatic Delineation of Cardiac Substructures On Noncontrast CT Be Used for Cardiac Toxicity Analysis?. Med Phys 43(6):3783, 2016. e-Pub 2016. PMID: 28047965.
Liu A, Mohan R, Liao Z. SU-F-T-150: Comparing Normal Tissue Irradiated Volumes for Proton Vs. Photon Treatment Plans On Lung Patients. Med Phys 43(6):3496, 2016. e-Pub 2016. PMID: 28047411.
Liao Z, Lee J, Komaki R, Gomez DR, O’Reilly M, Allen P, Fossella F, Heymach J, Choi NC, Delaney T, Hahn S, Lu C, Cox JD, Mohan R. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. Best of ASCO, ASCO 2016 Annual Meeting, 2016. e-Pub 2016.
Fried D, Meier J, Mawlawi O, Zhou S, Ibbott G, Liao Z, Court L. MO-DE-207B-07: Assessment of Reproducibility Of FDG-PET-Based Radiomics Features Across Scanners Using Phantom Imaging. Med Phys 43(6):3705-3706, 2016. e-Pub 2016. PMID: 28047514.
Giaddui T, Chen W, Yu J, Lin L, Simone CB, Yuan L, Gong YU, Wu QJ, Mohan R, Zhang X, Bluett JB, Gillin M, Moore K, O'Meara E, Presley J, Bradley JD, Liao Z, Galvin J, Xiao Y. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. Radiat Oncol 11:66, 2016. e-Pub 2016. PMID: 27142674.
Liao Z, Lee J, Komaki R, Gomez DR, O'Reilly M, Allen PK, Fossella F, Heymach J, Choi N, Delaney T, Hahn S, Lu C, Cox JD, Mohan R. A Bayesian randomization trial of IMRT vs. PSPT for locally advanced non-small cell lung carcinoma. The 35th ESTRO 2016 Annual Meeting E35-2458, 2016. e-Pub 2016.
Hong J, Liao Z, Zhuang Y, Levy LB, Sheu T, Heymach JV, Nguyen QN, Xu T, Komaki R, Gomez DR. Prognostic factors as a function of disease-free interval after definitive (chemo)radiation for non-small cell lung cancer using conditional survival analysis. Am J Clin Oncol. e-Pub 2015. PMID: 26535988.
Liu W, Liao Z, Li H, Li X, Zhu XR, Mohan R. Robust optimization of intensity-modulated proton therapy for lung cancer. Radiation Oncology, 2015. e-Pub 2015. PMID: 25708992.
Milbury K, Chaoul A, Engle R, Liao Z, Yang C, Carmack C, Shannon V, Spelman A, Wangyal T, Cohen L. Couple-based Tibetan yoga program for lung cancer patients and their caregivers. Psychooncology 24(1):117-20, 2015. e-Pub 2015. PMID: 24890852.
Liu W, Schild S, Chang J, Liao Z, Wen Z, Shen J, Stoker J, Wong W, Sahoo N, Herman M, Mohan R, Bues M. SU-F-BRD-01: a novel 4D robust optimization mitigates interplay effect in intensity-modulated proton therapy for lung cancer. AAPM 42(6):3525, 2015. e-Pub 2015.
Yang J, Xu T, Gomez DR, Nguyen Q, Yuan X, Song Y, Levy LB, Komaki RU, Liao Z. Single nucleotide polymorphisms in BMP2/BMP4/SMAD4 are associated with severe radiation pneumonitis in patients receiving definitive radiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 93(3):E440-E441, 2015. e-Pub 2015.
Zhou R, Yang J, Pan T, Milgrom S, Pinnix C, Shi A, Yang J, Liu Y, Nguyen Q, Gomez DR, Dabaja B, Balter P, Court LE, Liao Z. SU-E-J-129: atlas development for cardiac automatic contouring using multi-atlas segmentation. AAPM 42(6):3294, 2015. e-Pub 2015.
Yue J, Xu T, Pan T, Levy LB, Gomez DR, Lu C, Komaki RU, Mohan R, Liao Z. The predictive value of erial 18f-FDH PET/CT for recurrence and survival of locally advanced non-small cell lung cancer after concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys 93(3):E430-E431, 2015. e-Pub 2015.
Komaki RU, Wei X, Allen PK, Holliday E, Farooqi A, Lin SH, Balter P, Mohan R, Liao Z, Cox JD. Factors associated with severe pneumonitis for limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 93(3):E436-E437, 2015. e-Pub 2015.
Swanick CW, Naik NS, Liao Z, Allen PK, Welsh J, Komaki R, Chang JY, O'Reilly MS, lin SH, Gomez DR. Toxicity and local control with intensity-modulated radiation therapy (IMRT) using a simultaneous integrated boost (SIB) hypofractionated approach for non-small cell lung cancer (NSCLC). Int J Radiat oncol Biol Phys, 2015. e-Pub 2015. PMID: 25467928.
Tang C, Lee MS, Gomez D, Levy LB, Zhuang Y, Lu C, Liao Z, Komaki R. Effects of chemotherapy regimen and radiation modality on hematologic toxicities in patients receiving definitive platinum-based doublet chemoradiation for non-small cell lung cancer. Am J Clin Oncol, 2015. e-Pub 2015. PMID: 26165417.
Zhou R, Gomez DR, Nguyen Q, Zhuang Y, Xu T, Liu Y, Yang J, Levy LB, Komaki RU, Liao Z. Predictors of in-field local control and overall survival in inoperable non-small cell lung cancer after concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys 93(3):E422, 2015. e-Pub 2015.
He LR, Qiao W, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer 15:1095, 2015. e-Pub 2015. PMID: 25777421.
Fried D, Mawlawi OR, Zhang L, Fave X, Zhou S, Tucker SL, Ibbott GS, Liao Z, Court LE. Prognostic value and potential use of quantitative imaging features from pretreatment FDG-PET in stage III NSCLC. Int J Radiat oncol Biol Phys 93(3):E388, 2015. e-Pub 2015.
Liu Y, Xu T, Pang Q, Zhuang Y, Tsao A, Lu C, Komaki RU, Liao Z, Gomez DR. EGFR and KRAS mutations and disease outcomes in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 93(3):E435-E436, 2015. e-Pub 2015.
Kountourakis P, Correa AM, Hayashi Y, Hofstetter WL, Komaki R, Vaporciyan AA, Rice DC, Walsh GL, Bhutani MS, Ross WA, Liao Z, Swisher SG, Ajani JA. In patients with clinical t2nomo esophageal cancer: surgery first or preoperative chemo-radiation?. International Journal of Gastrointestinal Oncology, 2015. e-Pub 2015.
Xu, T, Meng QT, Gomez DR, Levy LB, Komaki RU, Mohan R, Liao Z. Serum Troponin T levels are associated with radiation dose to heart during definitive chemoradiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 93(3):E411-E412, 2015. e-Pub 2015.
Logan LK, Tang C, Heymach J, Swisher SG, Lin SH, Liao Z, Gomez DR. A prospective analysis of factors affecting successful clinical trial enrollment and randomization in the context of a randomized study of aggressive local therapy in oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 93(3):E362-E363, 2015. e-Pub 2015.
Shi A, Allen PK, Myles B, Wang J, Chang JY, Gomez DR, Komaki RU, Liao Z, Lin SH. Intensity modulated radiation therapy for 572 esophageal cancer: one us institutions clinical experience. Int J Radiat Oncol Biol Phys 93(3):E161, 2015. e-Pub 2015.
Li H, Liu W, Park P, Matney J, Liao Z, Chang J, Zhang X, Li Y, Zhu RX. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. J Appl Clin Med Phys 15(5):4810, 2014. e-Pub 2014. PMID: 25207565.
Liu W, Liao Z, Schild S, Park P, Li H, Li Y, Li X, Shen J, Anand A, Sahoo N, Dong L, Bues M, Zhu X, Mohan R. SU-E-T-452: impact of respiratory motion on robustly-optimized intensity-modulated proton therapy to treat lung cancers. AAPM, 2014. e-Pub 2014.
Jiang S, Liao L, Li Y, Wang X, Li H, Zhu X, Sahoo N, Gillin M, Hojo Y, Sun J, Chang JY, Liao Z, Grosshans D, Frank S, Zhang X. Su-e-p-06: a novel hybrid planning approach to allow more patients benefited by the intensity modulated proton therapy. AAPM, 2014. e-Pub 2014.
Yang J, Wu H, Wei S, Xiong H, Fu X, Qi Z, Jiang Q, Li W, Hu G, Yuan X, Liao Z. HPV seropositivity joints with susceptibility loci identified in GWASS at apoptosis associated genes to increase the risk of esophageal squamous cell carcinoma (ESCC). BMC Cancer 14(1):501, 2014. e-Pub 2014. PMID: 25008389.
Fried D, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, Court L. Mo-a-brd-04: prognostic value and reproducibility of pretreatment ct texture features in stage III non-small cell lung cancer. AAMP, 2014. e-Pub 2014.
Gomez D, O'Reilly M, Levy LB, Welsh J, Lin SH, Komaki R, Liu Z, Wei Q, Liao Z. Circulating mir-155 predicts for acute esophageal toxicity in patients with non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 87(2), 2013. e-Pub 2013.
Taylor MB, Liao Z, Bluett J, Kerr MD, Li H, Sahoo N, Gillin MT, Zhu X, Zhang X. Improving passive scattering proton therapy plan quality by optimizing compensator parameters. AAPM, 2013. e-Pub 2013.
Chen YP, Zhang L, Liao Z, Komaki R, Cox J, Balter P, Mohan R, Dong L. Comparison of tumor shrinkage in proton and photon therapy of lung cancer, 2013. e-Pub 2013.
Fakhreddine M, Liao Z, Zhuang Y, Bhardwaj V, Tucker S, Skinner H, Heymach JB, Gomez DR, Komaki R, Welsh J. Poor glycemic control during radiochemotherapy contributes to reduced local control and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(35):569, 2012. e-Pub 2012.
McAvoy S, Gomez D, Allen PK, Rineer J, Liao Z, Chang JY, Welsh J, Palmer MB, Cox JD, Komaki R. Efficacy and toxicity of re-irradiation with proton beam therapy for non-small cell lung cancer: an updated institutional experience. Oncology 26(1):7, 2012. e-Pub 2012.
Briere T, Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. Absolute lung volume considerations for radiation pneumonitis. ASTRO 2011 Annual Meeting, 2011. e-Pub 2011.
Swisher SW, Hofstetter W, Komaki R, Correa A, Erasmus J, Liao Z, Lee JH, Maru D, Mehran R, Patel S, Phan A, Rice D, Roth J, Vaporciyan AA, Walsh G, Ajani A. Improved long-term outcome with chemoradiotherapy strategies in locoregionally advanced esophageal cancer. Southern Thoracic Surgical Association, 2011. e-Pub 2011.
Quan E, Chang J, Liao Z, Xia T, Liu H, Balter P, Zhang X. Automated VMAT treatment planning for stage III lung cancer: how does it compare with IMRT?. Medical Physics(28):3671, 2011. e-Pub 2011.
Oberije C, Liao Z, De Ruysscher D, Tucker S, Lambin P. Development and external validation of a model for prediction of radiation-induced dyspnea: an approach combining clinical data with information from literature. Int J Radiat Oncol Biol Phys, 2010. e-Pub 2010.
Gomez DR, Tucker SL, Martel MK, Zhuang Y, Balter PA, Lopez JL, Jiang Z, Komaki R, Cox JD, Liao Z. Predictive dosimetric factors for high-grade esophagitis in patients treated for non-small cell lung cancer (NSCLC) with definitive 3D conformal therapy (3D-CRT), intensity modulated radiation therapy (IMRT), or proton beam therapy (PBT). Int J Radiat Oncol Biol Phys, 2010. e-Pub 2010.
Vinogradskiy Y, Tucker S, Liao Z, Martel M. Incorporating gross tumor volume location information into the modeling of radiation pneumonitis. Int J Radiat Oncol Biol Phys, 2010. e-Pub 2010.
Jiang Z, Zhuang Y, Komaki R, Jeter M, O'Reilly M, Gomez D, Lin SH, Lu C, Blumenschein G, Liao, Z. Prognostic factors for clinical outcomes and treatment-related late toxicities of inoperable non-small cell lung cancer (NSCLC) after definitive intensity-modulated radiotherapy (IMRT). Int J Radiat Oncol Biol Phys, 2010. e-Pub 2010.
Liao Z, Wei Q, Martel MK, Gomez D, Liu Z, Guan X, Zhuang Y, Lu C, Komaki R, Tucker SL. Incorporating SNPs as biomarkers to improve the fit of the lyman model for radiation pneumonitis. Int J Radiat Oncol Biol Phys, 2010. e-Pub 2010.
Yuan X, Liao Z, Komaki R, Liu Z, Tucker SL, Mao L, Martel M, Cox JD, Milas L, Wei Q. Heterozygous CT genotype of TGF Beta 1 at t869c was associated with a worse outcome in patients with non-small-cell lung cancer treated with definitive radiotherapy. 13th World Conference on Lung Cancer (ID# 6211), San Francisco, CA, 2009. e-Pub 2009.
Wang X, Cleeland C, Mao L, Williams L, Johnson VE, Krishnan S, Liao Z, Mobley GM. sTNF-R1 is associated with the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. Proc Am Soc Clin Oncol (ID# 3041), 2009. e-Pub 2009.
Liao Z, Yuan X, Komaki R, Liu Z, Tucker SL, Mao L, Martel M, Cox JD, Milas L, Wei Q. Association between heterogous CT genotype of TGF-Beta 1 gene at rs1982073:t869c and the outcomes of patients with non-small cell lung cancer treated with definitive radiotherapy. Oncology - ARS 23(4):11, 2009. e-Pub 2009.
Komaki R, Liao Z, Jeter M, O'Reilly M, Wei X, Allen P, Chang JY, McAleer M, Cox JD, Kies M. A phase I study of concurrent CPT-11/cisplatin and celecoxib with radiation therapy for patients with unresectable non-small cell lung cancer (NSCLC). Oncology - ARS 23(4):12, 2009. e-Pub 2009.
Yuan XL, Liao Z, Liu ZS, Wang L, Tucker SL, Mao L, Wang X, Martel M, Komaki R, Cox JD, Milas L, Wei AQ. Single nucleotide polymorphism at rs1982073:t869c of the TGF Beta-1 gene was associated with the risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiotherapy. J Thor Oncol, 2008. e-Pub 2008.
Liengsawangwong R, Liu HH, Khan M, Jeter M, Bucci MK, Allen PK, Komaki R, Cox JD, Liao Z. Esophageal cancer : the pattern of recurrence from m.d. anderson experiences. Int J Radiat Oncol Bio Phys, 2008. e-Pub 2008.
Sonis S, Jacquin P, Randolph P, Harari P, Grunberg S, Liao Z, Bolek T, Elting L, Keefe D. Prevalence of mouth and throat soreness (mts) in patients undergoing lung cancer treatment, with adverse impact on functional and quality of life outcomes. Int J Radiat Oncol Biol Phys, 2008. e-Pub 2008.
Liu HH, Tucker SL, Wei X, Jin HK, Yom SS, Martel M, Mohan R, Cox J, Komaki R, Liao Z. Analyses of risk for acute esophagitis and its influential predictors in inoperable non-small cell lung cancer patients treated with definitive radiation therapy. Int J Radiat Oncol Bio Phys, 2008. e-Pub 2008.
Settle SH, Bucci MK, Palmer M, Liu HH, Liengsawangwong R, Guerrero TM, McAleer MF, Cox JD, Komaki R, Liao Z. PET/CT fusion with treatment planning CT (TPCT) shows predominant pattern of locoregional failure in esophageal patients treated with chemoradiation (CRT) is in gross tumor volume (GTV). Int J Radiat Oncol Bio Phys, 2008. e-Pub 2008.
Liao Z, Komaki R, Liu HH, Chen Y, Jin HK, Wei X, Wang SL, Martel M, Mohan M, Cox JD, Tucker TL. Comparison of toxicity scoring systems for radiation pneumonitis: impact on risk estimates among patients with non-small cell lung cancer. Int J Radiat Oncol Bio Phy, 2008. e-Pub 2008.
Wei X, Allen PK, Liao Z, Chang YC, Guerrero TM, Cox JD, Komaki R. Survival and toxicity outcomes in patients with limited small-cell lung cancer. Int J Radiat Oncol Bio Phys, 2008. e-Pub 2008.
Cen P, Ajani JA, Correa AM, Lee JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA. Adenocarcinoma of the lower esophagus with barrett’s or without barrett’s: differences in patients survival after preoperative chemoradiation. J Clin Oncol 26(15S):4524, 2008. e-Pub 2008.
Komaki R, Sejpal SV, Wei X, Allen P, Chang JY, Liao Z, Mohan R, Dong L, Amos R, Cox JD. Reduction of bone marrow suppression for patients with stage III NSCLC treated by proton and chemotherapy compared with IMRT and chemotherapy. PTCOG 47 Abstract Book:14, 2008. e-Pub 2008.
Stevens C, Rice D, Forster K, Liao Z, Guerrero T, Correa A, Vaporciyan A, Smythe WR. Extrapleural pneumonectomy followed by IMRT: results of a phase I/II study. Proc Am Soc Clin Oncol, 23:(16S), Part I of II, 7178, 2005. e-Pub 2005.
Izzo JG, Wu TT, Luthra R, Luthra MG, Swisher S, Aggarwal BB, Bresalier RS, Milas L, Liao Z, Hittelman WN, Ajani J. Association of activated transcription factor NF-Kappa B with chemo-radiotherapy resistance and poor outcome in esophageal adenocarcinoma. j clin oncol 23:(16S), Part I of II, 4029, 2005. e-Pub 2005.
Izzo JG, Wu T, Malhotra U, Ensor J, Luthra R, Chao CK, Swisher SG, Liao Z, Aggarwal BB, Hittelman WN, Ajani JA. Transcription factor nfkb a potential molecular marker for predicting and improving treatment efficacy in esophageal cancer. Proc Am Soc Clin Oncol, 24:(18S):10065, 2005. e-Pub 2005.
Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter W, Liao Z, Komaki R, Rashid A, Hamilton SR, Wu T. Number of lymph nodes with metastasis predict survival in patients with esophageal or esophagogastric junction adenocarcinoma treated with preoperative chemoradiation. Proc Am Soc Clin Oncol, 23:(16S): Part I of II, 4046, 2005. e-Pub 2005.
Komaki R, Allen P, Glisson B, Lu C, Fossella F, Liao Z, Jeter M, Stevens CW, Chang JY, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (L-SCLC) with concurrent chemotherapy (CHT). Proc Am Soc Clin Oncol, 23:(16S): Part I of II, 7158, 2005. e-Pub 2005.
Komaki R, Spitz MR, Wu X, Chang JY, Allen PK, Milas L, Fossella FV, Stevens CW, Liao Z, Cox JD. Mutagen sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. Proc Am Soc Clin Oncol 22:7232, 2004. e-Pub 2004.
Liao Z, Liu HJ, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei QY. Polymorphisms of thymidylate synthase gene predict local or distant recurrence after preoperative chemoradiation in esophageal cancer. 1st official conference of international society gastrointestinal oncology. Gastrointest Cancer Res, 2004. e-Pub 2004.
Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9(6):476-484, 2003. e-Pub 2003. PMID: 14740977.
Swisher S, Ajani JA, Komaki R, Putnam J, Walsh G, Liao Z, Yao J, Faust J, Wu TT, Roth J. CPT-11-taxotere-5-fu regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with resectable esophageal or GEJ carcinoma. Proc Am Soc Clin Oncol 22:1093, 2003. e-Pub 2003.
Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF, Vaporciyan A, Ahamad A, Dong L, Salehpour M, Komaki R, Stevens CW. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 55:606-161, 2003. e-Pub 2003.
Liao Z, Chen Y, Komaki R, Cox JD, Milas L. A phase I study combining thoracic radiation (RT) with celecoxib in patients with non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 22:216 (#867), 2003. e-Pub 2003.
Liao Z, Chen Y, Cox JD, Komaki R, Milas L. Phase I study combining thoracic radiation (RT) with celecoxib (celex) in patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC). J Clin Oncol 22:106, 2003. e-Pub 2003.
Gopal R, Tucker SL, Liao Z, Stevens CW, Komaki R, Starkschall G. The local dose-function loss relationship for irradiated lung. Proceeding of 84th Annual Meeting American Radium Society, Las Croabas, Puerto Rico, 2002. e-Pub 2002.
Taylor N, Liao Z, Stevens CW, Kelly JF, Komaki R. Postoperative radiotherapy increases local regional control of patients with stage IIIa non-small cell lung cancer treated with induction chemotherapy followed by surgery. Proceeding of 84th Annual meeting American Radium Society, Las Croabas, Puerto Rico, 2002. e-Pub 2002.
Gopal R, Tucker SL, Liao Z, Stevens CW, Komaki R, Starkschall G. The local dose-function loss relationship for irradiated lung. Cancer J 8(6):486, 2002. e-Pub 2002.
Taylor NA, Liao Z, Stevens CW, Putnam JB, Walsh G, Allen P, Cox JD, Komaki R. Concurrent chemo-radiation results in equivalent local and overall outcome as induction chemotherapy followed by surgery for clinical stage IIIA non-small cell lung cancer. Int J Radiat Oncol Biol Phys 54 (2 Suppl):102, 2002. e-Pub 2002.
Liao Z, Jing J, Zhang Z, Swisher S, Ajani JA, Komaki R. Surgical resection may increase survival of patients with clinical stage II and III esophageal cancer treated with concurrent chemoradiation. Cancer J 8(6):486, 2002. e-Pub 2002.
Taylor N, Liao Z, Stevens CW, Kelly JF, Komaki R. Postoperative radiotherapy increases local regional control of patients with stage IIIa non-small cell lung cancer treated with induction chemotherapy followed by surgery. Cancer J 8(6):486, 2002. e-Pub 2002.
Komaki R, Lee JS, Milas L, Kaplan B, Allen P, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou VA, Khuri F, Herbst RD, Kies MS, Blunenschein GR, Glisson BS, Hong WK, Morice RC, Cox JD. Phase III trial of amifostine with chemoradiaiton for inoperable non-small cell lung cancer (NSCLC): does amifostine protect cancer cells. Int J Radiat Oncol Biol Phys 54 (2 Suppl):105, 2002. e-Pub 2002.
Gopal R, Starkschall G, Tucker S, Liao Z, Kelly J, Stevens C, Komaki R. The effects of radiation therapy, chemotherapy and the radioprotector amifostine on the diffusion capacity of patients with non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 51:22 (#33), 2001. e-Pub 2001.
Ahamad A, Forster K, Smythe W, Liao Z, Kelly J, Komaki R, Stevens C. Adjuvant IMRT for malignant mesothelioma. Int J Radiat Oncol Biol Phys 51:397 (#2326), 2001. e-Pub 2001.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, et al. Randomized phase III study of amifostine in patients treated with chemoradiation for inoperable stage II-III non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 51:19 (#28), 2001. e-Pub 2001.
Kaplan B, Stevens CW, Kelly J, Liao Z, Allen P, Komaki R. Atypical bronchial carcinoid tumors have a high incidence of loco-regional failure. Int J Radiat Oncol Biol Phys 51:351 (#2241), 2001. e-Pub 2001.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, et al. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). J Clin Oncol 20:325a (#1298), 2001. e-Pub 2001.
Kelly JF, Wu X, Komaki R, Stevens CW, Liao Z, Detry M, Honn SE, Bondy ML, Spitz MR. Lymphocyte mutagen sensitivity correlates significantly with gender, histology, and radiation toxicity in lung cancer patients. Int J Radiat Oncol Biol Phys 48:232, 2000. e-Pub 2000.
Zinner RG, Fossella FV, Komaki R, Jung M, Jhingran A, Glisson BS, Pisters KM, Stevens CW, Khuri FR, Kurie JM, Lee JS, Herbst RS, Liao Z, Hong WK. Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 19:510a, 2000. e-Pub 2000.
Liao Z, Komaki RU, Lee JS, Kelly J, Stevens C, Allen P, et al. Twice a day irradiation increased locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB NSCLC. Radiology 217(P):261, 2000. e-Pub 2000.
Hanus MC, Komaki RU, Stevens CW, Kelly JF, Liao Z. Comparison of dose-volume histogram and pulmonary function tests in NSCLC following 3D radiation therapy. Radiology 217(P):408, 2000. e-Pub 2000.
Parker P, Cohen L, Chavez L, Baum G, Pisters KM, Liao Z, Mehran R. The association between provider characteristics and beliefs about psychosocial care in oncology.

Book Chapters

Liao, Z, Xu, T, Komaki, R. Radioprotectors in the Management of Lung Cancer, 303-319, 2023.
Schoenhals JE, Brooks ED, Cortez MA, Syedin SN, Niknam S, Xiaohong W, Cadena AP, Li XS, Gomez DR, Liao Z, and Welsh JW. Translational Research and Immunotherapy in Lung Cancer. In: Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. Springer International Publishing AG Switzerland, 255-296, 2016.
Selek U, Bolukbasi Y, Topkan E, and Liao Z. Esophageal Cancer. In: Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. Springer International Publishing AG Switzerland, 297-324, 2016.
Lin SH, Liao Z. Esophageal cancer. In: Radiation Oncology: A Question Based Review. Lippincott Williams & Wilkins, 2011.
Lin SH, Liao Z. Esophageal cancer. In: Decision Making in Radiation Oncology. Springer, 2011.
Liao Z, Komaki R, Cox JD. The esophagus. In: The 9th edition of Radiation Oncology. 9. Elsevier, 2009.
Liao Z, Fossella F, Komaki R. Combinations of radiation therapy and chemotherapy for non-small cell lung carcinoma. In: Lung Cancer. 3. Blackwell Publishing, 283-351, 2008.
Liao Z, Liu HH, Komaki R. Evaluation of treatment related toxicity and clinical outcome in lung cancer radiochemotherapy. In: Image Guided Radiotherapy for Lung Cancer. 1. Taylor & Francis Group, LLC, 2008.
Liao Z, Mason KA, Milas L. Chemopreventive and therapeutic uses of cyclooxygenase-2 inhibitors in lung cancer. In: Cancer research at the leading edge. Nova Science, 1-29, 2007.
Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?. In: Drugs, 821-845, 2007.
Wistuba LL, Liao Z, Milas L. Molecular biology of lung cancer. In: Tumors of the Chest, 67-80, 2006.
Milas L, Mason KA, Liao Z, Ang KK. Combinations of taxanes and lonising radiation. In: Multimodal concepts or integration of cytotoxic drugs and radiation therapy. Springer-Verlag, 35-51, 2006.
Liao Z, Raju U, Mason KA, Milas L. Cycooxygenase-2 (cox-2) enzyme and its inhibition in tumor growth and therapy. In: Cancer target discovery and development. Humana Press, 571-596, 2005.
Gopal R, Cox JD, Liao Z, Stevens CW, Komaki R. Effects of amifostine on lung function in patients with non-small-cell lung cancer treated with radiation therapy and chemotherapy. In: Principles and practice of radiation oncology updates. 3rd, 2004.
Liao Z. Esophagus. In: Practical essentials of intensity modulated radiation therapy. Lippincott Williams & Wilkins, 286-302, 2004.
Milas L, Mason K, Liao Z, Raju U, Husain A, Ang KK. Role of cyclooxygenase-2 (cox-2) and its inhibition in tumors biology and radiotherapy. In: Modification of radiation response, cytokines, growth factors, and other biological targets. Springer-Verlag Berlin Heidelberg, 241-258, 2003.
Nguyen QN, Komaki R, Gomez D, Liao Z. Chest tumors (nsclc) - proton therapy in early-stage and advanced lung tumors. In: Contemporary Radiation Therapy. Atheneu.

Letters to the Editor

Komaki R, Liao Z, Liu HH, Tucker SL, Rice D. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 66: 1595-1596, 2006.

Less

Selected Presentations & Talks

Local Presentations

2021. Thoracic & GI Proton Therapy Webinar. Conference. MD Anderson Cancer Center Proton Therapy Center. Houston, TX, US.
2020. Rad Onc 2020: Updates in Radiation Oncology at MD Anderson Cancer Center. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Proton Therapy for Lung Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Lung Cancer Workshop. Conference. NRG. Houston, TX, US.
2018. Lymphoma/Sarcoma/Thoracic: Stump the Professor. Conference. Nursing/Dosimetry/Radiation Therapy Program. Houston, TX, US.
2018. Lymphoma/Sarcoma/Thoracic: Stump the Professor. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. The Presentation, Diagnosis, Prevention, and Treatment of Lung Cancer. Conference. The Salt and Light Society. Houston, TX, US.
2012. Overview of Radiation Toxicity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Normal Tissue Reaction to Radiotherapy - The Other Side of the Edged Sword. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2011. Radiation Oncology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. SNP as a Predictor for the Risk of Radiation Pneumonitis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Moving Towards Personalized Adaptive Radiation Therapy (PART) Lung. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Malignant Pleural Mesothelioma: Role of Radiation therapy in MPM. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Ku Mai Cui innovative therapy for lung cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. COX-2 and its inhibitor as a molecular target for NSCLC. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Multidisciplinary treatment of cancer of the esophagus. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
1999. Mantle irradiation alone for stage I and II Hodgkin's disease. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2017. Proton Therapy for Inoperable Non-small Cell Lung Cancer: Will This Replace the Current XRT Strategies?. Conference. The University of Texas MD Anderson Cancer Center. Steamboat Springs, CO, US.
2011. Moving Toward Personalized Adaptive Radiation for Lung Cancer. Conference. 17th Annual Radiation Workshop at Round Top. Round Top, TX, US.
2005. Radiotherapy in management of lung cancer. Conference. Cancer Care. Great Falls, MT, US.
2003. COX-2 and thoracic malignancies and clinical trials. Conference. Texas Radiological Society. The Woodlands, TX, US.
2000. Pulmonary damage of cancer therapy. Conference. The University of Texas MD Anderson Cancer Center, US.
2000. Pulmonary damage of cancer therapy. Conference. Texas Radiological Society. Austin, TX, US.
2000. Pulmonary toxicity of radiation therapy and chemotherapy. Conference. Texas Radiology Society Annual Meeting. Austin, TX, US.

National Presentations

2023. Moderator: Oral Abstract Session. Invited. 2023 Multidisciplinary Thoracic Cancers Symposium. New Orleans, LA, US.
2023. Moderator: Major Challenges and Opportunities Facing Us in 2023. Invited. 2023 Multidisciplinary Thoracic Cancers Symposium. New Orleans, LA, US.
2022. QOL/Outcomes/Digital health, Poster Walk Professor. Invited. American Radium Society. Scottsdale, AZ, US.
2021. Advancement in Management of LA-NSCLC: Role of Biomarkers. Invited. American Radium Society. Virtual, US.
2020. Overview and lessons learned from Phase II and III Randomized controlled studies of proton therapy versus IMRT for locally advanced Non-small cell lung cancer. Invited. PTCOG-NA. Virtual, US.
2019. Combination of Radiotherapy with targeted or immunotherapy - Clinical trials for evidence based clinical decision. Invited. ASTRO 61st Annual Meeting. Chicago, IL, US.
2018. Disparities. Invited. NRG Proton Working Group Face to Face Meeting. Philadelphia, PA, US.
2017. Update of RTOG Protocol 1308. Invited. NRG. Philadelphia, PA, US.
2017. Update of Protocol RTOG 1308. Conference. NRG. Philadelphia, PA, US.
2017. Proton Beam Radiotherapy for Locally Advanced Disease. Conference. ASTRO. San Francisco, CA, US.
2017. Locally Advanced Tumor. Conference. ASTRO. San Francisco, CA, US.
2015. Making the Best Use of Radiotherapy Resources in Lung Cancer. Invited. ASTRO. San Antonio, TX, US.
2015. Proton Working Group Workshop. Conference. NRG Oncology. San Diego, CA, US.
2014. Discussant - Lung 2 Toxicity. Invited. 2014 ASTRO Annual Meeting. San Francisco, CA, US.
2014. Prospective Randomized Trials of Protons and Photons for LA-NSCLC. Invited. CARRI 2014 Annual meeting. New Orleans, LA, US.
2013. Serum TGF-B1 and VEGF are Associated with Tumor Burden and Tumor Response on PET to Radio(chemo)therapy in Patients with NSCLC. Conference. 2013 ASTRO Annual Meeting. Atlanta, GA, US.
2013. Recent Advancement in Particle Therapy for Thoracic Cancer. Invited. 59th Annual Meeting of the Radiation Research Society (RRS). New Orleans, LA, US.
2013. Physical and Biologically Targeted Personalized Treatment for NSCLC. Invited. Third Annual Tatar Cancer Symposium. Dayton, OH, US.
2012. Panelist, Impact of Genetic Factors, Autoimmunity and Co-morbidity on Radiotherapy Toxicity. Invited. ASTRO 2012 Annual Meeting. Boston, MA, US.
2012. IMRT vs. Protons in Stage III NSCLC. Conference. RTOG Semi-Annual Meeting. Philadelphia, PA, US.
2012. Locally Advanced Non-Small Cell Lung Cancer. Invited. RTOG Semi-Annual Meeting. Philadelphia, PA, US.
2012. Radiochemotherapy Related Lung Injury and Toxicity. Invited. C. Stratton Hill, Jr., MD and Friends of Cancer Research. Houston, TX, US.
2011. Lessons from Radiation Oncology Clinical Trials / Lung. Invited. NIH. Bethesda, MD, US.
2011. International Best of ASTRO. Invited. ASTRO Annual Meeting. Miami, FL, US.
2011. Absolute Lung Volume Considerations for Radiation Pneumonitis. Conference. ASTRO Annual Meeting. Miami, FL, US.
2011. Functional Promoter rs2868371 Variant of HSPB1 Associates With Radiation- Esophagitis in Patients With Non-Small Cell Lung Cancer Treated With Radiotherapy. Conference. ASTRO Annual Meeting. Miami, FL, US.
2011. Dose Constraints to Prevent Radiation-Induced Brachial Plexopathy in Patients Treated for Lung Cancer. Conference. ASTRO Annual Meeting. Miami, FL, US.
2011. Long Term Outcomes Comparing Three-Dimensional Conformal Radiation Therapy to Intensity Modulated Radiation Therapy with Concurrent Chemotherapy for the Treatment of Esophageal Cancer: The MD Anderson Experience. Conference. ASTRO Annual Meeting. Miami, FL, US.
2011. Follow-up and Quality of Life for Proton Therapy Patients with Lung Cancer. Conference. Proton Therapy Center. Houston, TX, US.
2011. Personalized Therapy for Lung Cancer - Other Side of the Story. Invited. Normal Tissue TRP Session at RTOG. Philadelphia, PA, US.
2011. Our Experience in Proton Therapy: The University of Texas MD Anderson Cancer Center Case Study. Invited. Proton Therapy Centers Conference. Philadelphia, PA, US.
2010. Incorporating SNPs as biomarkers to improve the fit of the Lyman model for radiation pneumonitis. Invited. 2010 ASTRO Annual Meeting. San Diego, CA, US.
2010. Predictive dosimetric factors for high-grade esophagitis in patients treated for non-small cell lung cancer (NSCLC) with definitive 3D conformal therapy (3D-CRT), intensity modulated radiation therapy (IMRT), or proton beam therapy (PBT). Invited. 2010 ASTRO Annual Meeting. San Diego, CA, US.
2010. Incorporating gross tumor volume location information into the modeling of radiation pneumonitis. Invited. 2010 ASTRO Annual Meeting. San Diego, CA, US.
2010. Prognostic factors for clinical outcomes and treatment-related late toxicities of inoperable non-small cell lung cancer (NSCLC) after definitive intensity-modulated radiotherapy (IMRT). Invited. 2010 ASTRO Annual Meeting. San Diego, CA, US.
2010. Development and external validation of a model for prediction of radiation-induced dyspnea: an approach combining clinical data with information from literature. Invited. 2010 ASTRO Annual Meeting. San Diego, CO, US.
2010. Translational Research Program: "SNPs as biomarker to guide personalized radiation therapy for lung cancer". Invited. RTOG Semi-Annual Meeting. Philadelphia, PA, US.
2009. Refresher Course: Imaging and role of radiation in gynecologic malignancies. Invited. 95th RSNA Scientific Assembly and Annual Meeting. Chicago, IL, US.
2009. Chinese Educational Session. Invited. 2009 ASTRO Annual Meeting. Chicago, IL, US.
2009. Early results of proton beam therapy and concurrent chemotherapy in advanced lung cancer in randomized trial. Invited. Proton Radiotherapy: An Emerging Treatment Modality for Common Malignancies at ASTRO Annual Meeting. Chicago, IL, US.
2008. Comparison of toxicity scoring systems for radiation pneumonitis: Impact on risk estimates among patients with non-small cell lung cancer. Invited. 2008 ASTRO Annual Meeting. Boston, MA, US.
2008. Effect of technological advance on outcomes in patients with unresectable, locally advanced non-small cell lung cancer. Invited. American Radium Society 90th Annual Meeting. Dana Point, CA, US.
2007. Radiation treatment of non-small cell lung cancer. Invited. Society for Interventional Radiology (SIR) Oncology 2007 Meeting. Houston, TX, US.
2006. Controversies in radiation therapy for resected and locally advanced resectable patients. Invited. M. D. Anderson Cancer Center Physician Network, 2nd Annual symposium. Kauai, HI, US.
2006. Novel radiation therapy strategies. Invited. M. D. Anderson Cancer Center Physician Network, 2nd Annual Symposium. Kauai, HI, US.
2006. New directions for management of lung cancer XRT and molecular targeting. Invited. Annual Meeting of American Radium Society. Maui, HI, US.
2006. Stage III NSCLC all patients should be treated with definitive chemoradiation not surgery. Invited. 6th M. D. Anderson Annual Oncology Update: Advances and Controversies. Park City, UT, US.
2005. Radiotherapy in management of lung cancer. Invited. Cancer Care 2005. Great Falls, MT, US.
2004. Molecular epidemiology data. Conference. Annual Esophageal Cancer and Barrett's Metaplasia Research Summit. Las Vegas, NV, US.
2004. XRT in locally advanced lung cancer. Invited. 4th Annual Oncology Update and Advances and Controversies. Steamboat Spring, CO, US.
2002. Cox-2 Inhibitors in clinical trials. Invited. Radiation Therapy Oncology Group Meeting. Philadelphia, PA, US.
2001. Twice-a-day irradiation increased locoregional control in patients with medically inoperable of surgically unresectable stage II-IIIB non-small cell lung cancer. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
1999. Status of female radiation oncologist in China. Invited. American Association of Women Radiologist, Radiological Society of North America. Chicago, IL, US.
1999. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long term follow-up and patterns of failure. Invited. The 41st Annual Meeting of the American Society for Therapeutic Radiology and Oncology. San Antonio, TX, US.
1998. Malt (mucosa associated lymphoid tissue) lymphoma with supradiaphragmatic presentation: natural history and patterns of failure. Invited. The 40th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Phoenix, AZ, US.
1997. Subdiaphragmatic stage I & II Hodgkin's disease-long term follow-up and prognostic factors. Invited. The 39th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Orlando, FL, US.
1996. Detailed long-term cost-utility and cost-benefit analysis of follow-up studies for patients enrolled in clinical trials: limited-staged small-cell lung cancer. Invited. Radiological Society of North America Annual Meeting. Chicago, IL, US.
1994. The effect of volume irradiated on radiation pneumonitis in mouse lung. Conference. The 36th Annual Meeting of the American Society for therapeutic Radiology and Oncology. San Francisco, CA, US.
1992. The effect of partial lung irradiation on morbidi0ty, mortality and damage in mouse lung. Conference. The 40th Annual Meeting of Radiation Research Society. Salt Lake City, UT, US.
1991. Unilateral nephrectomy does not precipitate latent renal functional damage after irradiation. Conference. The 39th Annual Meeting of Radiation Research Society. Dallas, TX, US.

International Presentations

2024. Personalized Management of Cancer Therapy Induced Toxicity. Invited. Radiotherapy in the Era of Targeted Treatment and Immunotherapy: Joint Symposium. Arter, Istanbul, TR.
2024. Advancement in Proton Therapy for Thoracic Cancers. Invited. 1st China Cancer Particle Radiotherapy Conference, 17th Jinan International Symposium of Radiation Oncology. Jinan, CN.
2019. Progress in research on radiation-induced heart injury. Invited. CSTRO. Shenzhen, CN.
2019. SBRT combined with immunotherapy for advanced stage lung cancer. Invited. CSTRO. Shenzhen, CN.
2019. Combination of immunotherapy with chemoradiation therapy for NSCLC. Invited. HISO. Hangzhou, CN.
2018. Lymphocytes as an organ at risk in radiotherapy. Invited. West China Hospital. Chengdu, CN.
2018. Tumor Radiotherapy. Invited. Yantai Yuhuangding Hospital. Yantai, CN.
2018. Biology-driven the development. Invited. CSTRO. Changsha, CN.
2018. Take home message from the first randomized trial of proton therapy for NSCLC. Invited. The 1st International Particle Radiotherapy and Clinical Research Summit Stanford Wuxi Radiation Therapy Symposium. Jinan, CN.
2017. The Success of Proton Therapy Depends on Precision. Invited. 14th National Meeting of Chinese Society of Therapeutic Radiation Oncology. Beijing, CN.
2017. Current status and future direction of particle beam therapy for lung cancer. Invited. The 58th Annual Meeting of the Japan Lung Cancer Society (JLCS2017). Yokohama,, JP.
2017. Precision Proton Treatment for Lung Cancer. Invited. The 12th Annual Academic Meeting of West Therapeutic Radiology and Oncology Association. Chongqing, CN.
2017. ESTRO-ASTRO: The use of novel technologies (e.g. protons) in NSCLC: Cutting edge combined modality therapies (Focus on NSCLC). Invited. ASTRO. Vienna, AT.
2017. Gastrointestinal. Invited. Best of ASTRO Philippines. Manila, PH.
2017. Lung. Invited. Best of ASTRO Philippines. Manila, PH.
2016. Role of SBRT and Proton Therapy on Precision Treatment of Lung Cancer. Invited. The 5th Biennial Meeting of International Chinese Society of Thoracic Surgery (ICSTS). Alisan, TW.
2016. Proton Therapy for Thoracic Cancer: What have we learned?. Invited. CSTRO. Chengdu, CN.
2016. The Role of Radiotherapy in the Treatment of Esophagus Cancer. Invited. Varian Medical Systems. Xiamen, CN.
2016. Proton Therapy for LA-NSCLC. Invited. Chinese Western Society of Oncology Group (CSWOG). Huhhot, CN.
2016. The Practice of Multidisciplinary Management for NSCLC in the Era of Targeted and Immunotherapy. Invited. The 7th Congress of Multidisciplinary Synthetic Therapy. Chengdu, CN.
2015. Re-Evaluation the Role of Radiation in Cancer Treatment. Invited. 12th Annual CSTRO. Chengdu City, CN.
2015. Re-Evaluation the Role of Radiotherapy in Cancer Treatment. Invited. Chinese Medical Association and Chinese Society of Therapeutic Radiology and Oncology. Chengdu, CN.
2015. The New Role of Radiation in Cancer Treatment. Invited. Zhejiang Cancer Hospital. Hangzhou, CN.
2015. Advanced in Radiation treatment for early stage NSCLC. Invited. The University of Texas MD Anderson Cancer Center and The Faculty of Medicine Siriraj Hospital, Mahidol University. Bankok, TH.
2015. Consideration in radiation dose escalation for lung cancer. Conference. The University of Texas MD Anderson Cancer Center GAP. Changsha, CN.
2015. Educating Radiation Oncologist in the USA: ACGME. Invited. IAEA. Shanghai, CN.
2014. Radiotherapy Quality Assurance in NRG (RTOG) Clinical Trials and International Collaboration. Invited. CSTRO. Nanjing, CN.
2014. Stress and Cancer, and potential role for Beta Blockers in Improving Survival Outcomes. Invited. West China Radiotherapy Group. Guiyang, CN.
2014. Prospective Randomized Trials of Protons and Photons for LA-NSCLC. Invited. PTCOG. Shanghai, CN.
2014. Hitachi user meeting, Prospective Randomized Trials of protons and photons for LA-NSCLC. Invited. PTCOG. Shanghai, CN.
2014. Role of Radiotherapy for Esophageal Cancer. Invited. Radiation Hope - GHOS. Moshi, TZ.
2014. Radiotherapy for Lung Cancer, From Photons to Protons. Invited. Thai Society of Therapeutic Radiology and Oncology. Pattaya, TH.
2014. The current role of radiotherapy in lung cancer managment. Invited. Wattanosoth Cancer Hospital (WSH). Bankok, TH.
2013. Molecular & Physical Targeted Therapy for Locally Advanced NSCLC. Invited. 2013 Hangzhou International Symposium of Oncology (HISO). Hangzhou, CN.
2013. IMRT for Thoracic Malignancies - what we have learned in the past decade. Invited. 2013 Western Region of Radiation Oncology Conference of China. Xi'an, CN.
2013. Examining the influence of incidentally using ACEI on survival outcomes in stage III non-small cell lung cancer patients treated with definitive radiotherapy. Conference. 2013 Annual Meeting - American Society of Clinical Oncology. Chicago, US.
2013. Current Advancement and Prospect of Esophageal Cancer Treatment in America. Invited. 2013 Tianjin International Symposium on the Progresses of Radiation Oncology - Thoracic Oncology. Tianjin, CN.
2013. Keynote Address. Invited. 8th PPRA-RTOG Annual Conference & Multicenter Cooperative Radiation Therapy Seminar. Changsha, CN.
2013. Treatment Related Pneumonitis: Rationale of Using Biologically and Physically Personalized Therapy. Invited. 37th Annual MD Anderson Radiation Oncology/Gilbert H. Fletcher Society Meeting. Kyoto, JP.
2013. The Current Status of Particle Therapy for Thoracic Cancers. Invited. Shanghai International Conference - SICRO VII. Shanghai, CN.
2012. Translational Medicine and Applications Round Table. Conference. 2012 International Symposium on Translational Medicine. Changsha, CN.
2012. Esophageal Cancer - Advances & Challenges. Invited. Tongji Medical School - Huazhong. Wuhan, CN.
2012. The Advances in the Treatment of Esophageal Carcinoma. Invited. 8th National Meeting - Chinese Society of Therapeutic Radiation Oncology (CSTRO). Beijing, CN.
2012. Current Status of Lung Cancer Treatment. Invited. Xinjiang Congress of Radiation Oncology Conference. Urumqui, CN.
2012. Current Status of Esophageal Cancer Treatment. Invited. Shandong Cancer Hospital. Jinan, CN.
2012. Current Status of Lung Cancer Treatment. Invited. Hunan Tumor Hospital & Institute. Changsha, CN.
2012. Critical Assessment of the Potential of Research Strategies to Improve Outcome of Advanced NSCLC. Invited. ESTRO 31st Annual Meeting. Barcelona, ES.
2012. Novel Therapies: Lung cancer and Women - Analysis of NLST - Women Participants Tarceva with or without RT, Molecular Targeted Treatment. Invited. ARRS 2012 Annual Meeting. Vancouver, CA.
2012. Adding Genetic Biomarker to Predictive Model. Invited. The 27th Conference on Clinical and Experimental Research in Radiation Oncology (CERRO). Les Menuires, FR.
2011. PET Utilization in Radiotherapy for Lung Cancer. Invited. PET/CT Conference. Beijing, CN.
2011. How to Follow Up the Acute and the Late Toxicity With New Emerging Therapies. Invited. ECCO 16 / ESMO 36. Stockholm, SE.
2011. Comparison of Tumor Shrinkage in Proton and Photon Therapy of Lung Cancer. Conference. AAPM. Vancouver, CA.
2011. Panel Discussion: Case Presentation of Fresh Diagnosis Thoracic Cancer and a Recurrent Lung Case. Invited. International Conference for Chinese Radiation Oncologists and Medical Physicists. LiJiang, CN.
2011. Current & Future Patient Management for Thoracic Cancers. Invited. International Conference for Chinese Radiation Oncologists and Medical Physicists. LiJiang, CN.
2011. Status of Particle Therapy of Lung Tumors. Invited. The Skandion Clinic. Uppsala, SE.
2010. Post-operative radiotherapy in NSCLC - Who should be treated?. Invited. Standards and Trends: In the Treatment of Cancer and Hematologic Diseases. Armenia, CO.
2010. Multimodality Treatment of Esophageal Cancer. Invited. 2010 Chinese Society of Clinical Oncology (CSCO) Refresher Course. Beijing, CN.
2010. Radiation treatment and research in lung cancer. Invited. 6th Shanghai International Conference on Radiation Oncology (SICRO VI). Shanghai, CN.
2010. Using SNP as a biomarker for personalized radiation for NSCLC. Invited. The 25th CERRO Meeting. Les Menuires, FR.
2009. Personalized therapy for NSCLC: Advances, challenges, and opportunities. Invited. Conference on New Techniques of Radiation Oncology. Beijing, CN.
2008. Influence of advanced technology on outcome of patients with NSCLC: IMRT, IGRT, and beyond. Invited. International Radiation Oncology Symposium. Seoul.
2008. Impact of advanced technology on outcome of patients with NSCLC. Invited. The 3rd China Pan-Pearl-River Area Congress of Radiation Oncology. Fuzhou, CN.
2008. Treatment related pneumonitis: dose and volume, smoking status, and genetic factors. Invited. The 23rd CERRO Meeting. Les Menuires, FR.
2007. Poster: Image guided gated setup and treatment with implanted fiducials. Conference. IASLC 12th World Conference on Lung Cancer. Seoul.
2007. Discussant: technical advances on radiation therapy. Invited. IASLC 12th World Conference on Lung Cancer. Seoul.
2007. Traditional Chinese medicine combined with conventional cancer. Invited. 13th International Congress of Radiation Research. San Francisco, US.
2007. Treatment related toxicity in thoracic chemoradiation. Invited. The Second International Conference in Image Guided Radiation therapy. Chengdu, CN.
2007. Current status and future direction in the management of esophageal cancer. Invited. The 2nd Pan-Pearl-River Area Congress and International Symposium of Radiation Oncology. Chengdu, CN.
2006. Treatment related toxicity in thoracic radiation. Invited. The 5th Shanghai International Conference on Radiation Oncology (SICRO V). Shanghai, CN.
2006. Novel radiation therapy strategies. Invited. The 4th Chinese Conference on Oncology. Tianjin, CN.
2006. Introduction to evidence based medicine. Invited. The 5th Educational Seminar in Japan, M. D. Anderson Cancer Center Medical Exchange Program 2006. Kyoto, JP.
2005. Introduction to evidence based medicine. Invited. The 4th Educational Seminar in Japan, Learning Multidisciplinary Approaches to Cancer Treatment M. D. Anderson Cancer Center Medical Exchange Program 2005. Osaka, JP.
2005. Esophageal cancer in the West. Invited. The 1st International Conference on Esophageal Cancer. Henan, CN.
2005. Utilization of PET/CT in thoracic radiation oncology. Invited. GE PET/CT Conference. Tianjin, CN.
2005. Phase I clinical trial using selective cyclooxygenase-2 (COX-2) inhibitor celecoxib with concurrent thoracic irradiation in patients with poor prognosis non-small cell lung cancer (NSCLC). Invited. 11th World Conference on Lung Cancer. Barcelona, ES.
2005. Dose-volume analyses of postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Invited. The 2005 International Gastrointestinal Oncology Conference. Arlington, US.
2005. Target delineation for esophageal cancer. Invited. 3rd International Target Delineation Symposium for IMRT/3D CRT Treatment Planning. Avon, US.
2004. The current status of radiation therapy in the management of NSCLC. Invited. The 1st SINO-US Annual Seminar Series on Clinical Oncology East meets West. Shanghai, CN.
2004. Polymorphisms of thymidylate synthase gene predict local or distant recurrence after preoperative chemoradiation in esophageal cancer. Invited. First Official Conference of International Society Gastrointestinal Oncology. Arlington, US.
2003. COX-2 Inhibitor in cancer therapy clinical aspect. Invited. 17th Asia Pacific Cancer Conference. Bali, ID.
2003. COX-2 and Its Inhibition in tumor growth and therapy preclinical studies. Invited. 17th Asia Pacific Cancer Conference. Bali, ID.
2002. Prospective trials in radiation oncology overview of RTOG protocols. Invited. MDACC and Japan Medical Exchange Program Kyoto Seminar. Kyoto, JP.
2002. Postoperative radiotherapy increases local regional control of patients with stage IIIA non-small cell lung cancer treated with induction chemotherapy followed by surgery. Invited. Annual Meeting of American Radium Society. Las Croabas, PR.
2002. Does surgical resection in addition to concurrent chemoradiation increase survival in patients with clinical stage II-III esophageal cancer?. Invited. Annual Meeting of American Radium Society. Las Croabas, PR.
2000. Radiation therapy for lung cancer. Invited. 6th Turkish Thoracic and Cardiovascular Association Congress. Antalya, TR.
1999. Overview of RTOG in US. Invited. The Chinese Society of Radiation Oncology the 4th Annual Meeting. Wuhan, CN.
1999. The effect of combined chemotherapy and radiation therapy on the pulmonary function in patients with medically inoperable or unresectable stage II-III non-small cell lung cancer. Invited. American Radium Society Annual Meeting. London, GB.
1994. Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung. Invited. Department of Radiation Oncology Grand Rounds. Shanghai, CN.

Formal Peers

2022. Personalisation of chemoradiotherapy for lung cancer patients. Invited. University Hospital Carl Gustav Carus Dresden. Dresden, DE.
2020. Proton therapy for thoracic malignancies. Visiting. Huntsman Cancer Hospital,University of Utah. Salt Lake (Virtual Visit), UT, US.
2016. Proton Therapy for Thoracic Cancer: What have we learned?. Invited. Chang Gung Memorial Hospital LinKou. Taipei, TW.
2016. Proton Therapy for Thoracic Cancer: What have we learned?. Invited. Chang Gung Memorial Hospital LinKou. Taipei, TW.
2016. Proton Therapy for Thoracic Cancer: What have we learned?. Invited. China Medical University Hospital in Taichung. Taichung, Taiwan, US.
2016. Radiotherapy for LA-NCLC: From Photons to Protons. Invited. China Medical University Hospital in Taichung. Taichung, Taiwan, US.
2016. Proton Therapy for Thoracic Cancer: What have we learned?. Invited. Chinese Academy of Sciences. Hefei, CN.
2016. The Role of Radiotherapy in Precision Medicine for Lung Cancer. Invited. The First Jinlin International Radiation Oncology Annual Meeting and Radiation THerapy Quality Assurance and Contouring Forum. Nanjing, CN.
2016. Translational Research in Radiation. Visiting. Hunan Cancer Hospital,. Changsha, Hunan, CN.
2015. Change of Paradiam-Role of Radiation Therapy in Cancer Treatment. Invited. Tongji Hospital, Tongji Medical School, Hua Zhong Univeristy of Technology and Science. Wuhan, Hu Bei, CN.
2014. Introduction of MD Anderson Cancer Center and Current Status of Lung Cancer Treatment. Invited. The Central Hospital of Changsha City. Changsha, Hunan, CN.
2014. Update in Personalized Management of Lung cancer. Invited. Tongji Hospital, Huazhong University of Science and Technology. Wuhan, Hubei, CN.
2012. Update on A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, with Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence. Invited. MGH. Boston, US.
2011. Rationale for Using Advanced Technology in Thoracic Cancer. Invited. The Methodist Hospital System. Houston, TX, US.
2011. Visiting Professor, Using Advanced Technology in Radiotherapy for Thoracic Malignancies - Rationale and Practical Perspectives. Visiting. The Methodist Hospital. Houston, TX, US.
2011. Molecular Targeting Therapy for Non-Small Cell Lung Cancer. Invited. Tong Ji Hospital. Wuhan, CN.
2011. Intensity modulated radiation therapy for lung cancer. Invited. Sun Yat-Sien University Cancer Hospital. Guangzhou, Guangdong, CN.
2011. Visiting Professor, Treatment Related Pneumonitis: Impact of Advanced Technology in Radiation Therapy. Visiting. Huntsman Cancer Hospital, University of Utah. Salt Lake City, UT, US.
2011. Visiting Professor, Moving Towards Personalized Therapy for NSCLC. Visiting. Huntsman Cancer Hospital, University of Utah. Salt Lake City, UT, US.
2010. Translational research towards personalized radiotherapy for lung cancer. Invited. Tong Ji Hospital, Tongji University Medical School. Wuhan, Hu Bei, CN.
2010. Visiting Professor, Advances in lung cancer treatment. Visiting. University of Louisville School of Medicine. Louisville, KY, US.
2010. Proton therapy of thoracic tumors, post graduate course in proton therapy. Invited. Lionsalen - Umea University Hospital. Umea, SE.
2008. Visiting Professor, The MD Anderson Experience of Using IMRT for Lung Thoracic Cancers. Visiting. The Methodist Hospital Cancer Center. Houston, TX, US.
2008. Treatment related pneumonitis (TRP) in NSCLC: dose volume effect, smoking status, and genetic influence. Invited. Hokkaido University Graduate School of Medicine. Sapporo, JP.
2008. Introduction to evidence based medicine. Invited. The University of Texas M. D. Anderson Cancer Center. Sapporo, JP.
2008. The influence of advance technology on outcomes of patient with NSCLC-IMRT, IGRT and beyond. Invited. Samsung Medical Center, Sungkyunkwan university School of Medicine. Seoul.
2008. Impact of advanced technology on outcome of patients with NSCLC. Invited. Fujian Provincial Tumor Hospital. Fujian, China, CN.
2007. Visiting Professor. Visiting. Fudan University Cancer Hospital. Shanghai, CN.
2006. Treatment related toxicity in thoracic chemoradiation. Invited. Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College. Beijing, CN.
2006. Dosimetric predictive factors for treatment related lung toxicity in concurrent chemotherapy and thoracic irradiation. Invited. Tong Ji Hospital, Tong Ji University. Wuhan, CN.
2006. Treatment related toxicity in thoracic chemoradiation. Invited. Kyoto University Medical School. Kyoto, JP.
2006. Visiting Professor. Visiting. West China Hospital, Sichuan University. Chengdu, CN.
2005. Esophageal cancer in the West. Invited. Xiang Ya Hospital, Xiang Ya Medical School. Changsha, CN.
2005. Esophageal cancer in the West. Invited. Tianjin Medical University Cancer Institute and Hospital. Tianjin, CN.
2005. Utilization of PET/CT in thoracic radiation oncology. Invited. Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College. Beijing, CN.
2005. Esophageal cancer, from West to East. Invited. Beijing Tumor Hospital, Beijing University School of Medicine, College of Clinical Oncology. Beijing, CN.
2004. COX-2 and its inhibitors, from laboratory to clinic. Invited. Tong Ji Hospital, Tong Ji University. Wuhan, CN.
2004. COX-2 and its inhibitors, from laboratory to clinic. Invited. Central South University. Changsha, CN.
2004. Visiting Professor. Visiting. Xiang Ya Hospital, Xiang Ya Medical School, Central South University. Changsha, CN.
2004. Esophageal cancer. Invited. Baylor College of Medicine. Houston, TX, US.
2003. COX-2 and its inhibitors as a molecular target for cancer prevention and treatment. Invited. Xiangya Hospital, School of Medicine, Central South University. Changsha, Hunan, CN.
2003. COX-2 and its inhibitors as a molecular target for cancer prevention and treatment. Invited. Xiangya Medical School, Southern Central University. Changsha, US.
2003. Introduction to M. D. Anderson Cancer Center. Invited. The University of Houston, Asian American Studies, US.
2003. COX-2 and its inhibitors: clinical aspect. Invited. Yokohama City University. Yokohama, JP.
2003. Visiting Professor. Visiting. Tong Ji University, Tongji Medical School. Wuhan, CN.
2003. New development of diagnosis and treatment of cancer. Invited. University of Houston. Houston, TX, US.
2003. Treatment of locally advanced non-small cell lung cancer-where are we. Invited. Cancer Hospital/ Cancer Institute Fudan University. Shanghai, CN.
2003. Treatment of locally advanced non-small cell lung cancer where are we?. Invited. Fudan University Cancer Hospital. Shanghai, CN.
2003. Treatment of locally advanced non-small cell lung cancer-where are we?. Invited. Tong Ji Hospital, Tong Ji University. Wuhan, CN.
2002. New Standard in the treatment of locally advanced unresectable NSCLC. Invited. Tohoku University Medical Society. Sendai, JP.
2002. New standard in the treatment of locally advanced unresectable NSCLC. Invited. Tohoku Medical Society. Sendai, JP.
2002. Treatment of esophageal cancer. Invited. Sun Yat-Sien University Cancer Hospital. Guangzhou, CN.
2002. New treatment modality for non-small cell lung cancer. Invited. Beijing Tumor Institution. Beijing, CN.
2002. Multidisciplinary treatment of esophageal cancer. Invited. Fudan University Cancer Hospital. Shanghai, CN.
2001. Radiation therapy for non-small cell lung cancer the past, current, and future. Invited. Tong Ji Medical University. Wuhan, Hu Bei, CN.
2001. Esophageal cancer in USA. Invited. Tong Ji Medical University. Wuhan, CN.
1994. Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung. Invited. Shanghai Tumor Hospital and Institution. Shanghai, CN.

Less

Grant & Contract Support

Date:	2022 - 2027
Title:	Nanoplasmic Quantification of Tumor-derived Extracellular Vesicles for Early Lung Cancer Prognosis
Funding Source:	Tulane University
Role:	Co-I

Date:	2022 - 2027
Title:	Radiation-mediated cardiotoxicities among autoimmune hosts
Funding Source:	Thomas Jefferson University
Role:	Co-I

Date:	2021 - 2026
Title:	Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	P01CA261669

Date:	2021 - 2026
Title:	Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients
Funding Source:	NIH/NCI
Role:	PI
ID:	R01HL157273

Date:	2020 - 2025
Title:	Investigating Patient, Tumor, and Treatment Factors Underlying Sensitivity of Cancers and Normal Tissues to Proton vs Photon Radiation: Project 1 – Understanding normal tissue toxicity to identify patients likely to benefit from proton therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1PO1CAOh s241508-02

Date:	2020 - 2023
Title:	Understanding and Modeling Biological Effects and Normal Tissues Complications Based on Clinical Outcomes for Proton Radiotherapy
Funding Source:	CPRIT
Role:	Co-I

Date:	2019 - 2021
Title:	Clinical Potential of a Monte Carlo-Based Biological Dose Optimization System for Intensity-Modulated Particle Therapy
Funding Source:	Institutional Research Grant
Role:	Co-I
ID:	2020-00057972-Y1

Date:	2019 - 2025
Title:	Nanobiotix Strategic Alliance
Funding Source:	Nanobiotix CO and MDACC
Role:	PI
ID:	00056641

Date:	2019 - 2024
Title:	Remote Peer Review System
Funding Source:	Varian Medical Systems, Inc
Role:	Co-I

Date:	2019 - 2021
Title:	Proton Therapy to Reduce Heart Damage for Lung Cancer Patients
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21CA222749-01A1

Date:	2019 - 2024
Title:	Mitigating Motion Uncertainties in Spot Scanned Proton Therapy Employing Perturbation Theory to Treat Locally Advanced Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP6708

Date:	2019 - 2024
Title:	CKI in reducing cancer therapy induced toxicity: Strategic Collaboration between ZhenDong Pharmaceutical and MDACC
Funding Source:	Shanxi Zhendong Pharmaceutical Co., Ltd
Role:	Co-I
ID:	57387

Date:	2019 - 2025
Title:	UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1
Funding Source:	NIH/NCI
Role:	Co-I
ID:	UG1CA233329

Date:	2019 - 2022
Title:	Yoga Program for Couples Coping with Lung Cancer
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	RSG PCSM - 130533

Date:	2018 - 2024
Title:	Dyadic Yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R37CA231522

Date:	2017 - 2019
Title:	Imaging & Serum Biomarkers for Detection of Cardiac Injury from Radiotherapy
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2016 - 2021
Title:	Dependence of cardiac troponin expression on the magnitude and distribution of radiation exposure in NSCLC patients after chemoradiation
Funding Source:	NIH
Role:	PI

Date:	2016 - 2021
Title:	One blood test to predict survival for precision medicine
Funding Source:	NIH - Subcontract
Role:	Co-I

Date:	2016 - 2018
Title:	Novel STAT inhibitors for the treatment of radiation-induced fibrosis
Funding Source:	CPRIT - Subcontract
Role:	Co-I

Date:	2016 - 2019
Title:	Understanding biological and physical factors affecting response to proton therapy to improve its clinical effectiveness
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP160232

Date:	2015 - 2016
Title:	Role of PI3K/AKT and MAPK/ERK pathways on beta-adrenergic signaling in NSCLC cell lines
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	Long-term International Fellowship

Date:	2015 - 2018
Title:	Radiomics approaches to personalized cancer therapy
Funding Source:	NIH
Role:	Co-I
ID:	14671

Date:	2015 - 2020
Title:	A Randomized Trial of Incentives for Research Participation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA197332-01

Date:	2015 - 2017
Title:	Couple-based meditation program for patients with metastatic lung cancer and their partners
Funding Source:	NIH
Role:	Co-I

Date:	2015 - 2016
Title:	Diffusion-weighted magnetic resonance imaging for early response assessment of neoadjuvant chemoradiation for squamouse cell carcinoma of the esophagus
Funding Source:	UTMDACC SINF
Role:	PI
ID:	Sister Institution Network Fund Application

Date:	2014 - 2016
Title:	Couple-based meditation program for patients with metastatic lung cancer and their partners
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R21

Date:	2014 - 2018
Title:	Improving the clinical effectiveness and understanding of the biophysical basis - Project 1: Randomized Clinical Trials to Exploit the Physical and Biophysical Properties of Protons including Reduction in Dose Bath with Protons
Funding Source:	NIH/NCI
Role:	Protocol Chair
ID:	2U19CA021239-35

Date:	2014 - 2016
Title:	Dependence of cytokine expression on genotypes and radiation modality
Funding Source:	NIH/NCI
Role:	PI
ID:	R21

Date:	2013 - 2015
Title:	Nanopore-peptidomics to predict response to chemoradiotherapy for lung cancer
Funding Source:	NIH/NCI
Role:	PI

Date:	2013 - 2015
Title:	Reducing the symptom burden produced by aggressive cancer therapies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA026582-31

Date:	2013 - 2017
Title:	Couple-based meditation for lung cancer patients and partners
Funding Source:	American Cancer Society (ACS)
Role:	Co-I

Date:	2010 - 2012
Title:	Huachansu in non-small cell lung cancer
Funding Source:	American Association for Cancer Research (AACR)
Role:	PI

Date:	2008 - 2014
Title:	Optimizing proton therapy - project 1: proton dose escalation and proton vs. photon randomized trials for non-small cell lung cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P01CA021239-32

Date:	2008 - 2014
Title:	Optimizing proton therapy - project 4: achieving "what you see is what you get" in proton therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P01CA021239-32

Date:	2008 - 2010
Title:	Inflammatory cytokines associated symptom burden in nsclc patients receiving cxrt
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA132109-01A1

Date:	2007 - 2011
Title:	BOI mucositis study
Funding Source:	Amgen, Inc
Role:	Co-I
ID:	CS2006-00016455AB

Date:	2007 - 2010
Title:	Phase i/ii trial of sorafenib with concurrent thoracic radiotherapy for poor prognosis non-small cell lung cancer (nsclc)
Funding Source:	Bayer Pharmaceuticals Corporation
Role:	PI
ID:	CS2007-00021089EB

Date:	2005 - 2007
Title:	Cytokines and symptoms in lung cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	CA 109286

Date:	2005 - 2010
Title:	International center of tcm for cancer
Funding Source:	NIH/NCCAM
Role:	Co-Principal Investigator for clinical trials
ID:	CA121503

Date:	2004 - 2005
Title:	NCI R21 planning grant to create the international center of tcm for cancer
Funding Source:	NIH/NCCAM
Role:	CO-PI
ID:	CA108084

Date:	2003 - 2004
Title:	Integration of molecular targeting into cpt-11-radiotherapy combination for esophageal cancer
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Investigator

Date:	2003 - 2005
Title:	Pulmonary complications of cancer therapy. project 3: assessment, modeling, application of lung dose response in radiation therapy in: multidisciplinary research proposal
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Project Leader

Date:	2003 - 2003
Title:	MRP planning grant to create the international center of tcm for cancer
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	Co-I

Date:	2002 - 2006
Title:	Research grant award: a phase i translational study using combination of chemo-radiation and cox-2 inhibitor celebrex for patients with unresectable esophageal cancer
Funding Source:	Pharmacia, Inc
Role:	PI
ID:	CS2002-0000679

Date:	2002 - 2005
Title:	A translational prospective clinical trial using selective cox-2 inhibitor and radiation for poor performance status and inoperable/unresectable non-small cell lung cancer patients
Funding Source:	Radiological Society of North America, Research and Education Foundation
Role:	PI
ID:	CS2002-00006791DH01

Date:	2001 - 2006
Title:	International radiology education program grant to teach the teachers from emerging nations
Funding Source:	Radiological Society of North America, Research and Education Foundation
Role:	Co-PI

Title:	Adaptive randomized trial of 3-d crt and imrt for lung cancer
Funding Source:	American Society of Clinical Oncology
Role:	PI

Title:	The interplay between immunotherapy, concurrent chemoradiation and therapy induced senescence on cardiopulmonary adverse events in lung cancer patients
Funding Source:	NIH/NCI
Role:	PI

Title:	Improving the Clinical Effectiveness and Understanding of the Biophysical Basis of Proton Therapy
Funding Source:	MDACC - Core D
Role:	Co-I

Title:	Identifying Biomarkers and Therapeutic Targets of Chemoradiotherapy- and Immune Checkpoint Inhibitor-Induced Cardiopulmonary Adverse Sequelae in Lung Cancer Patients
Funding Source:	NIH/NCI
Role:	PI
ID:	1 R01 CA261959-01

Title:	Dependence of cardiac troponin expression on the magnitude and distribution of radiation exposure in NSCLC patients after chemoradiation
Funding Source:	NIH/NCI
Role:	PI

Title:	Building the educational foundation of a teacher and mentor for international
Funding Source:	Radiological Society of North America
Role:	PI

Title:	Dependence of cardiac troponin expression on the magnitude and distribution of heart radiation dose in nsclc patients after chemoradiation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Title:	One blood test to predict survival - A semi-mechanistic model for precision radiotherapy
Funding Source:	NIH/NCI
Role:	Co-PI

Title:	Assessing kinetics of tumor response and its correlation with pathological response using fdg-pet/ct for patients with esophageal cancer treated with preoperative chemoradiation
Funding Source:	American Cancer Society
Role:	PI

Title:	Ku Mai Cai: Effects against pneumonitis and lung cancer
Funding Source:	NIH/NIBIB
Role:	PI

Title:	Personalized adaptive radiation therapy for non-small cell lung cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	RO1

CV information above last modified March 03, 2025

Zhongxing Liao, M.D.

About Dr. Liao

In the News

What is chemoradiation?

4 advances in radiation therapy for lung cancer treatment

Exploring proton therapy's effectiveness on the most common form of lung cancer

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Liao Laboratory

Radiation Therapy

Radiation Treatment Center

Radiation Oncology Department

Radiation Oncology Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer

What is chemoradiation? 